USRE43009E1 - Apparatus and method for reducing subcutaneous fat deposits by electroporation - Google Patents

Apparatus and method for reducing subcutaneous fat deposits by electroporation Download PDF

Info

Publication number
USRE43009E1
USRE43009E1 US12/572,005 US57200509A USRE43009E US RE43009 E1 USRE43009 E1 US RE43009E1 US 57200509 A US57200509 A US 57200509A US RE43009 E USRE43009 E US RE43009E
Authority
US
United States
Prior art keywords
electrodes
needle
electroporation
high voltage
electrode
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US12/572,005
Inventor
Victor I. Chornenky
Ali Jaafar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angiodynamics Inc
Original Assignee
Angiodynamics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/931,672 external-priority patent/US6892099B2/en
Application filed by Angiodynamics Inc filed Critical Angiodynamics Inc
Priority to US12/572,005 priority Critical patent/USRE43009E1/en
Application granted granted Critical
Publication of USRE43009E1 publication Critical patent/USRE43009E1/en
Assigned to JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT reassignment JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT SECURITY AGREEMENT Assignors: ANGIODYNAMICS, INC.
Assigned to ANGIODYNAMICS, INC. reassignment ANGIODYNAMICS, INC. RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: JPMORGAN CHASE BANK N.A., AS ADMINISTRATIVE AGENT
Assigned to JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT reassignment JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT SECURITY AGREEMENT Assignors: ANGIODYNAMICS, INC.
Assigned to JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT reassignment JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ANGIODYNAMICS, INC.
Assigned to ANGIODYNAMICS, INC. reassignment ANGIODYNAMICS, INC. RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Assigned to JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT reassignment JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Assignors: ANGIODYNAMICS, INC.
Anticipated expiration legal-status Critical
Assigned to JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT reassignment JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ANGIODYNAMICS, INC.
Assigned to ANGIODYNAMICS, INC. reassignment ANGIODYNAMICS, INC. RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Assigned to ANGIODYNAMICS, INC. reassignment ANGIODYNAMICS, INC. RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/327Applying electric currents by contact electrodes alternating or intermittent currents for enhancing the absorption properties of tissue, e.g. by electroporation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/05Electrodes for implantation or insertion into the body, e.g. heart electrode
    • A61N1/0502Skin piercing electrodes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/328Applying electric currents by contact electrodes alternating or intermittent currents for improving the appearance of the skin, e.g. facial toning or wrinkle treatment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00571Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for achieving a particular surgical effect
    • A61B2018/00613Irreversible electroporation

Definitions

  • the present invention relates generally to electroporation in-vivo and specifically to apparatus and method for reducing subcutaneous fat deposits and/or for performing virtual face lifts and/or body sculpturing.
  • “Cosmetic surgery” is a phrase used to describe broadly surgical changes made to a human body with the usual, though not always, justification of enhancing appearance. This area of medical practice constitutes an ever-growing industry around the world. Obviously, where such a procedure fails to deliver an enhanced appearance, the procedure fails to meet the desired goal.
  • One of the reasons that the majority of current procedures fail to deliver upon their promise is that, for the most part, current procedures are invasive, requiring incisions and suturing, and can have serious and unpleasant side effects, including but not limited to scarring, infection, and loss of sensation.
  • a face-lift is intended to enhance facial appearance by removing excess facial skin and tightening the remaining skin, thus removing wrinkles.
  • a face-lift is traditionally performed by cutting and removing portions of the skin and underlying tissues on the face and neck. Two incisions are made around the ears and the skin on the face and neck is separated from the subcutaneous tissues. The skin is stretched, excess tissue and skin are removed by cutting with a scissors or scalpel, and the skin is pulled back and sutured around the ears. The tissue tightening occurs after healing of the incisions because less skin covers the same area of the face and neck and also because of the scars formed on the injured areas are contracting during the healing process.
  • Another laser procedure involves using optical fibers for irradiation of the subcutaneous tissues, such as disclosed in U.S. Pat. No. Re36,903.
  • This procedure is invasive and requires multiple surgical incisions for introduction of the optical fibers under the skin.
  • the fibers deliver pulsed optical radiation that destroys the subcutaneous tissues as the tip of the fiber moves along predetermined lines on the face or neck.
  • Debulking the subcutaneous fat and limited injury to the dermis along the multiple lines of the laser treatment results in contraction of the skin during the healing process, ultimately providing the face lift.
  • the drawback of the method is its high price and possibility of infection.
  • Electrosurgical devices and methods utilizing high frequency electrical energy to treat a patient's skin including resurfacing procedures and removal of pigmentation, scars, tattoos and hairs have been developed lately, such as disclosed in U.S. Pat. No. 6,264,652.
  • the principle drawback of this technology is collateral damage to the surrounding and underlying tissues, which can lead to forming scars and skin discoloration.
  • liposuction is an invasive procedure that involves inserting a suction device under the skin and removing fat tissues.
  • a suction device that involves inserting a suction device under the skin and removing fat tissues.
  • this procedure has resulted in patient deaths when too much tissue was removed. Assuming successful removal of excess fat tissue, further invasive surgery may be required to accomplish desired skin tightening.
  • EP electroporation
  • the term “electroporation” (EP) is used herein to refer to the use of a pulsed electric field to induce microscopic pores in the biological membranes, also commonly called a cell wall, of living cells.
  • the cell membrane separates the inner volume of a cell, or cytosol, from the extracellular space, which is filled with lymph.
  • This membrane performs several important functions, not the least of which is maintaining gradients of concentration of essential metabolic agents across the membrane. This task is performed by active protein transporters, built in the membrane and providing transport of the metabolites via controlled openings in the membrane.
  • the active protein transporters, or pumps which routinely provide transport of various metabolic agents, especially proteins, across the cell membrane, use either the energy of positive ions (hydrogen or sodium ions) passing from the positive potential of the intracellular space to the negative potential of the cytosol, or the energy of negative ions (chlorine ions) for movement across the membrane in the opposite direction.
  • This energy supply for the protein transporters is provided by maintaining the potential difference across the membrane, which, in turn, is linked to the difference in concentrations of sodium and potassium ions across the membrane. When this potential difference is too low, thousands of the active transporters find themselves out of power.
  • the survivability of electroporated cells is limited As the electric field amplitude and/or duration of pulses, increases, this limit, usually referred to as the “upper EP limit” of electroporation, is inevitably achieved. Above the upper EP limit, the number and sizes of pores in the cellular membrane become too large for a cell to survive. Multiple pulses cause approximately the same effect on the cells as one pulse with a duration equal to the total duration of all applied pulses. After application of an electrical pulse above the upper electroporation limit the cell cannot repair itself by any spontaneous or biological process and dies.
  • the upper EP limit is defined by the combinations of the amplitudes of electric field and pulse durations that cause cellular death.
  • the vulnerability of cells to electroporation depends on their size: the larger the cell, the lower the electric field and duration of a pulse capable of killing it. If cells of different sizes are exposed to the same electric field, the largest cells will die first. Thus, this ability of electroporation to discriminate cells by their sizes may be used to selectively kill large cells in the human body.
  • the apparatus comprises a high voltage pulse generator and an applicator having two or more electrodes utilized in close mechanical and electrical proximity with the patient's skin to apply electrical pulses thereto.
  • the applicator may include at least two electrodes with one electrode having a sharp tip and another having a flat surface.
  • High voltage pulses delivered to the electrodes create at the tip of the sharp electrode an electric field high enough to cause death of relatively large subcutaneous fat cells by electroporation. Moving the electrode tip along the skin creates a line of dead subcutaneous fat cells, which later are metabolized by the body. Multiple applications of the electrode along predetermined lines on the face or neck create shrinkage of the skin and the subcutaneous fat reduction under the treated area.
  • the electroporation in-vivo employed in the disclosed method is a non-invasive treatment of subcutaneous fat, which, as was previously described before, involves application of high amplitude electric pulses between external electrodes to cause death by electroporation of the subcutaneous fat cells.
  • Fat cells being typically larger than other cells of the body, are more easily killed by electroporation treatment than are smaller lean muscle cells.
  • the electric field, applied to the external electrodes is efficient for cell killing in the subcutaneous layer of fat tissue directly under the skin.
  • the amplitude of the field significantly decreases with increasing the depth of the deposits of fat cells.
  • the deeper penetration of the electric field may be achieved by increasing the distance between electrodes with simultaneous increase in the operating voltage.
  • the present invention provides an apparatus and method for creation of a controlled electroporation injury to deep subcutaneous fat tissues that, with the healing that follows, leads to permanent loss of the fat cells in the treated tissue.
  • an electric field capable of killing fat cells in deep subcutaneous deposits may be applied by a set of needle electrodes, configured for placement deeply under the skin.
  • An apparatus according to the current invention comprises a voltage pulse generator, an applicator with two or multiple electrodes of different shapes and sizes, and a cable connecting the electrodes to the pulse generator.
  • the pulse generator produces a sequence of high voltage pulses of predetermined amplitude, duration and number to cause necrosis in a treated area of the subcutaneous tissue.
  • a method of weight loss and body sculpturing in accord with the present invention comprises application of electrical pulses to the electrodes positioned under the skin in a treatment area of the subcutaneous fat tissue.
  • the amplitude, duration and number of applied pulses are selected to cause necrosis of fat cells at a predetermined distance around the needles in the subcutaneous tissue.
  • a number of sites in a predetermined pattern are exposed to electroporation.
  • the treated area contracts as the electroporated cells die and are metabolized by the body, thus reducing volume of fat tissue and providing desired change of body contours.
  • the injury to the tissues made by electroporation is very selective, targeting only large fat cell and not damaging the epidermis, the most external layer of the skin.
  • the electrical field is applied only to the deep subcutaneous fat deposits, no electric field is applied to the skin of the patient.
  • FIG. 1 is a schematic illustration of an electroporation system for treatment of deep subcutaneous fat deposits.
  • FIG. 2 shows time diagrams for high voltage pulses during EP treatment wherein FIG. 2a illustrates unipolar pulsing and FIG. 2b illustrates bipolar pulsing.
  • FIG. 3 illustrates a one-needle applicator with two electrodes.
  • FIG. 4 illustrates an embodiment of an applicator comprising one needle in combination with an external patch electrode wherein FIG. 4a provides a plan view and FIG. 4b provides a cross-sectional view taken along viewing plane 4 b— 4 b.
  • FIG. 5 illustrates an embodiment of the applicator comprising an array of needle electrodes.
  • FIG. 6 illustrates in orthogonal views in FIGS. 6a and 6b an embodiment of the applicator comprising needle electrodes without insulated parts.
  • FIG. 1 shows schematically an electroporation system 100 for in-vivo treatment of deep subcutaneous fat deposits.
  • the system 100 includes a high voltage electroporation pulse generator 101 connected by an appropriate connector 102 to an applicator 103 .
  • Applicator 103 may include a handle 104 and a pair of needle 120 and 122 extending therefrom. Handle 104 may be used by the operator for the safe and efficacious placement of the needles 120 and 122 in a selected-for-treatment anatomical site.
  • Needles 120 and 122 may include proximal insulated portions 124 and 126 , respectively, central uninsulated portions 128 and 130 , respectively, and distal insulated portions 132 and 134 .
  • distal portions 132 and 134 includes sharpened ends or tips 136 and 138 , respectively.
  • an operator of system 100 will use handle 104 to push the tips 136 and 138 through the skin 150 of the patient into a deep subcutaneous fat deposit 152 .
  • the sharpened tips 136 and 138 facilitate penetration of the skin 150 and fat tissue 152 while minimizing pain or serious discomfort to the patient.
  • Insulated proximal portions 124 and 126 of needles 120 and 122 respectively, provide electrical insulation from the skin 150 during an EP treatment. That is, this insulation prevents a current flow from the needles 120 and 122 through the skin and with it an associated discomfort of the patient.
  • the insulated distal portions 132 and 134 of needles 120 and 122 helps to avoid spark discharges between the tips during high voltage electroporation pulsing.
  • Central portions 128 and 130 form the electrodes for the system 10 , which as noted are uninsulated.
  • the electrodes 128 and 130 are in close electrical contact with the surrounding tissue 152 and provide a pulsed electrical field, as indicated by shown by arrows 160 , to the treatment zone 162 between and around electrodes 128 and 130 , as indicated by dotted line 162 .
  • the treatment zone is actually a three dimensional zone extending in all directions from the electrodes 128 and 130 .
  • the larger treatment zone 162 will be where the cells are actually killed. It should be mentioned that not all cells die at any point of the treatment zone. The smaller fat cells will survive. As was mentioned early, cell killing by electroporation is selective on the cell size and the upper EP limit is higher for small cells. Small fat cells, for which applied electric field is below the upper electroporation limit, will survive any reasonable number of electric pulses without any morphological or functional damage and will stay in the tissue. Also, there is no electroporation treatment for the tissues interfacing the insulated parts of the needles.
  • a computer 170 connected by an appropriate connector 172 to EP generator 101 may be provided to control the whole procedure of EP treatment: the predetermined amplitude, duration, and number of EP pulses supplied to the electrodes 128 and 130 .
  • the EP pulses may be applied with a repetition rate of about 1 to about 50 Hz and may have a current peak of about 0.5 to about 10 A depending on the size and shape of electrodes.
  • the voltage of the EP pulses can be in the range of about 50 V to about 5000 V with a duration from about 10 microseconds to about 10.0 milliseconds depending on the location of the treated segment of the body, the sizes and shapes of the electrodes, and the distance between the electrodes. Regardless of the possible configuration of the electrodes and the voltages applied to the treatment volume, the voltage applied to an individual subcutaneous fat cell should fall in the range of about 2 to about 10 V per cell to be able to kill it.
  • the electric field applied to the treated volume of cells must be above the upper EP limit for the cells.
  • the probability of cell killing increases if longer or multiple pulses are employed.
  • high voltage pulses of different waveforms may be used for the EP treatment.
  • the pulses may be rectangular or exponential in shape, be unipolar (positive or negative only) or bipolar (positive and negative).
  • Bipolar rectangular pulses are known to be very efficient in cell killing by electroporation. This is because both directions of the electrical field, positive and negative, are equally efficient in creating pores in cellular membranes, and the electric field strength, contrary to the exponential pulses, stays high during the whole pulse.
  • electroporation is a process related to the difference in the energy of the porous and non-porous membrane in the presence of an electric field. The energy difference depends on the square of the amplitude (or strength) of the electric field (i.e., E 2 ) and does not depend on the sign or polarity (+ or ⁇ ) of the electric field.
  • bipolar pulsing is free from these drawbacks.
  • problems such as metal depositions from the electrodes or chemical decomposition of tissue during treatment are largely if not completely avoided.
  • balanced pulses namely, high efficiency in cell killing and freedom from electrolytic effects
  • balancing of two pulses of the opposite polarities may be easily achieved by using a pulse generator having a direct current blocking capacitor electrically coupled in series to the needle electrodes.
  • FIGS. 2a and 2b plots of high voltage EP pulses against time are shown.
  • the upper curve shows a plot of rectangular balanced pulses
  • the preferred embodiment shows exponential balanced pulses.
  • FIG. 2b depicts rectangular and exponential unipolar pulses in the upper and lower curves, respectively.
  • Needle applicator 300 comprises a single needle 310 with two axially separated electrodes 328 and 330 of opposite polarity insulated from each other and separated by insulator 308 .
  • the needle may be made of a hollow tube carrying inside two conductors connecting electrodes 328 and 330 via cable 302 to the output of the EP generator, not shown in the figure.
  • Proximal end 325 of the needle 310 is covered with an insulation layer to protect the skin of the patient during treatment from an electric current and discomfort associated with it.
  • the needle 310 may be made of insulating material or of a metal piece electrically insulated from the electrodes 328 and 330 . Additionally, distal end 333 may have a sharp tip 337 .
  • the electric field between electrodes 328 and 330 is shown by lines 360 .
  • Dotted lines 362 delineate the treatment zone, where the electric field is the highest and where actual killing cells by electroporation occurs.
  • FIG. 4 Yet another embodiment 400 of the needle applicator is shown in FIG. 4 in two substantially orthogonal views, namely FIGS. 4a and 4b .
  • Applicator 400 comprises a needle 410 with an electrode 428 combined with a patch electrode 430 .
  • Patch electrode 430 is placed on the skin 450 of the patient near the treatment site, which is delineated by a dotted line 462 .
  • Needle 410 may include a sharp tip 436 and insulated proximal and distal portions 442 and 433 on either side of electrode portion 428 of needle 410 .
  • the electrical field lines generated between electrodes 428 and 430 are indicated by lines 460 .
  • High voltage EP pulses during treatment are delivered to the electrodes 428 and 430 via appropriate conductors 454 and 455 , respectively, which are connected to the connector 402 coupled to the output of the EP generator 101 , not shown in the FIG. 4 .
  • FIG. 4b shows cross section of the applicator. Dotted line 462 delineates the treatment zone around the electrode 428 where the fat cells are killed.
  • FIG. 5 shows yet another implementation 500 of a needle applicator in accord with the present invention.
  • Applicator 500 comprises a handle 504 supporting a needle frame 505 .
  • Needle frame 505 supports a plurality of needles 520 of one polarity (positive) and a plurality of needles 522 including an electrode of the other polarity (negative), with each needle of one polarity being adjacent to one or more needles of the other polarity.
  • Handle 504 is connected via connector 502 to the output of the EP generator 101 (not shown in the Figure).
  • the needles 520 and 522 in the needle array alternately have positive and negative polarity.
  • the needles 520 and 522 may include a proximal insulated portion 524 and 526 , central electrode portions 528 and 530 , and distal insulated portions 536 and 538 respectively. Each needle 520 and 522 will also preferably include sharp tip 536 and 538 .
  • the needles are placed preferably normally to the skin.
  • One of benefits of this configuration is that the tissue electroporation occurs in thin cylindrical layers around the electrodes and later, during healing process, macrophages from nearby blood vessels will travel a shorter distance to the damaged cells. Thus, this configuration may accelerate the disposal of the dead fat cells.
  • Applicator 600 may include a handle 604 and a pair of needle 620 and 622 extending therefrom. Handle 604 may be used by the operator for the safe and efficacious placement of the needles 620 and 622 in a selected-for-treatment anatomical site.
  • the sharpened tips 636 and 638 facilitate penetration of the skin 650 and fat tissue 652 while minimizing pain or serious discomfort to the patient.
  • the whole needles 620 and 622 perform function of electrodes; that is, the needles 620 and 622 do not include insulated portions as in the previously described embodiments.
  • needles 620 and 622 are connected to the EP generator (not shown in the Figures) providing high voltage pulses during treatment.
  • Electric field lines between electrodes 620 and 622 are shown by arrows 660 .
  • Dotted line 662 shows the treatment area of the fat tissue 652 where electroporation actually kills fat cells.
  • Needle electrode diameters may fall in a range of about 0.3 mm to about 1.0 mm, which corresponds to the standard of minimally invasive size.
  • the distance between adjacent needles may be in a range of several mm to several cm.
  • Applied voltage depending on the distance between needles and the size of the fat cells to be killed, may vary in a wide range from about 100 V to several hundreds and even thousands of volts. In any case the resultant electric field applied to the treated fat cells must be above their upper electroporation limit, or about 2 to about 10 V per cell.
  • the electroporation pulses during treatment may be applied simultaneously to all electrodes or in a sequence of sets of two to several electrodes throughout the whole treated area.
  • the number of pulses per treatment of a selected site may vary from several pulses to several tens of pulses. Preferred duration of the pulses is from about 10 microseconds to about 10 milliseconds.
  • a method for electroporation treatment of deep subcutaneous fat deposits comprises providing a high voltage pulse generator for generation EP pulses and a needle applicator.
  • the needle applicator or needle applicator and pad electrode may be placed by a physician in an anatomically selected site of treatment under ultrasound or other type of imaging guidance. After the needle placement a sequence of high voltage EP pulses is applied to the electrodes.
  • the electrodes may be placed in plurality of treatment sites in accordance with a treatment plan developed by a physician. Sequences of the high voltage EP pulses are repeatedly applied to the electrodes.
  • a subsequent electroporation treatment can then be performed with new treatment sites selected for the electroporation treatment. In this manner, then, a patient's body can be sculpted as desired.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Plastic & Reconstructive Surgery (AREA)
  • Electrotherapy Devices (AREA)

Abstract

An apparatus and method for minimally invasive treatment of deep subcutaneous fat deposits in lieu of cosmetic surgery is disclosed. The apparatus comprises a high voltage pulse generator connected to two or more needle electrodes at least one of which is configured for placement deeply under the skin in a treatment site of the patient's body. High voltage pulses, delivered to the electrodes, create an electric field that kills subcutaneous fat cells.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS
The present application claims priority from and is a continuation-in-part of U.S. patent application Ser. No. 09/931,672, filed Aug. 17, 2001, entitled Apparatus and Method for Reducing Subcutaneous Fat Deposits, Virtual Face Lift and Body Sculpturing by Electroporation, now U.S. Pat. No. 6,892,099, the specification and drawings of which are incorporated herein in their entirety by reference, which claims the benefit of U.S. Provisinal Application Ser. No. 60/267,106 filed Feb. 8, 2001 and U.S. Provisional Application Ser. No. 60/225,775, filed Aug. 17, 2000. The present application also claims priority from U.S. Provisional Patent Application Serial No. 60/358,443, filed Feb. 22, 2002, and entitled Apparatus and Method for Reducing Subcutaneous Fat Deposits by Electroporation, the specification and drawings of which are incorporated herein in their entirety by reference.
FIELD OF INVENTION
The present invention relates generally to electroporation in-vivo and specifically to apparatus and method for reducing subcutaneous fat deposits and/or for performing virtual face lifts and/or body sculpturing.
BACKGROUND OF INVENTION
“Cosmetic surgery” is a phrase used to describe broadly surgical changes made to a human body with the usual, though not always, justification of enhancing appearance. This area of medical practice constitutes an ever-growing industry around the world. Obviously, where such a procedure fails to deliver an enhanced appearance, the procedure fails to meet the desired goal. One of the reasons that the majority of current procedures fail to deliver upon their promise is that, for the most part, current procedures are invasive, requiring incisions and suturing, and can have serious and unpleasant side effects, including but not limited to scarring, infection, and loss of sensation.
One of the more common forms of cosmetic surgery is the “face-lift.” A face-lift is intended to enhance facial appearance by removing excess facial skin and tightening the remaining skin, thus removing wrinkles. A face-lift is traditionally performed by cutting and removing portions of the skin and underlying tissues on the face and neck. Two incisions are made around the ears and the skin on the face and neck is separated from the subcutaneous tissues. The skin is stretched, excess tissue and skin are removed by cutting with a scissors or scalpel, and the skin is pulled back and sutured around the ears. The tissue tightening occurs after healing of the incisions because less skin covers the same area of the face and neck and also because of the scars formed on the injured areas are contracting during the healing process.
Traditional face-lift procedures are not without potential drawbacks and side effects. One drawback of traditional cosmetic surgery is related to the use of scalpels and scissors. The use of these devices sometimes leads to significant bleeding, nerve damage, possible infection and/or lack of blood supply to some areas on the skin after operation. Discoloration of the skin and alopecia (baldness) are other possible side effects of the standard cosmetic surgery. The overall quality of the results of the surgery is also sometimes disappointing to the patients because of possible over-corrections, leading to undesired changes in the facial expression. Additionally, face-lift procedures require a long recovery period before swelling and bruising subside.
The use of lasers to improve the appearance of the skin has been also developed. Traditional laser resurfacing involves application of laser radiation to the external layer of the skin—the epidermis. Destruction of the epidermis leads to rejuvenation of the epidermis layer. The drawback of the laser resurfacing procedure is possible discoloration of the skin (red face) that can be permanent.
Another laser procedure involves using optical fibers for irradiation of the subcutaneous tissues, such as disclosed in U.S. Pat. No. Re36,903. This procedure is invasive and requires multiple surgical incisions for introduction of the optical fibers under the skin. The fibers deliver pulsed optical radiation that destroys the subcutaneous tissues as the tip of the fiber moves along predetermined lines on the face or neck. Debulking the subcutaneous fat and limited injury to the dermis along the multiple lines of the laser treatment results in contraction of the skin during the healing process, ultimately providing the face lift. The drawback of the method is its high price and possibility of infection.
Electrosurgical devices and methods utilizing high frequency electrical energy to treat a patient's skin, including resurfacing procedures and removal of pigmentation, scars, tattoos and hairs have been developed lately, such as disclosed in U.S. Pat. No. 6,264,652. The principle drawback of this technology is collateral damage to the surrounding and underlying tissues, which can lead to forming scars and skin discoloration.
Other forms of cosmetic surgery are also known. One example is liposuction, which is an invasive procedure that involves inserting a suction device under the skin and removing fat tissues. As with other invasive surgical procedures, there is always a risk of infection. In addition, because of the invasive nature of the procedure, physicians usually try to minimize the number of times the procedure must be performed and thus will remove as much fat tissue as possible during each procedure. Unfortunately, this procedure has resulted in patient deaths when too much tissue was removed. Assuming successful removal of excess fat tissue, further invasive surgery may be required to accomplish desired skin tightening.
The prior art to date, then, does not meet the desired goal of performing cosmetic surgery in a non-invasive manner while causing minimal or no scarring of the exterior surface of the skin and at the same time resulting in the skin tightening.
The term “electroporation” (EP) is used herein to refer to the use of a pulsed electric field to induce microscopic pores in the biological membranes, also commonly called a cell wall, of living cells. The cell membrane separates the inner volume of a cell, or cytosol, from the extracellular space, which is filled with lymph. This membrane performs several important functions, not the least of which is maintaining gradients of concentration of essential metabolic agents across the membrane. This task is performed by active protein transporters, built in the membrane and providing transport of the metabolites via controlled openings in the membrane. Normally, the active protein transporters, or pumps, which routinely provide transport of various metabolic agents, especially proteins, across the cell membrane, use either the energy of positive ions (hydrogen or sodium ions) passing from the positive potential of the intracellular space to the negative potential of the cytosol, or the energy of negative ions (chlorine ions) for movement across the membrane in the opposite direction. This energy supply for the protein transporters is provided by maintaining the potential difference across the membrane, which, in turn, is linked to the difference in concentrations of sodium and potassium ions across the membrane. When this potential difference is too low, thousands of the active transporters find themselves out of power.
Inducing relatively large pores in the cell membrane by electroporation creates the opportunity for a fluid communication through the pores between the cytosol and the extracellular space that may lead to a drastic reduction of these vitally important gradients of concentrations of the metabolic agents and thus a reduction in the potential difference across the membrane. Uncontrolled exchange of metabolic agents, such as ions of sodium, potassium, and calcium between a living cell and the extracellular space imposes on the cell intensive biochemical stress.
When a cell is undergoing biochemical stresses the major biochemical parameters of the cell are out of equilibrium and the cell cannot perform its routine functions. Invasion of very high concentration of calcium ions through membrane pores from the interstitial space between cells, where the calcium ion concentration is about 100 times higher than in the cytosol, can create such stresses by reducing the potential difference across the membrane. In an attempt to repair itself, the cell starts working in a damage control mode: an emergency production of actin filaments is triggered that extend across the large pores in the membrane in an attempt to bridge the edges of the pores, pull the edges together, and thereby seal the membrane. In muscle cells the calcium ion invasion may cause lethal structural damage by forcing the cell to over-contract and rupture itself. Small pores in the membrane created by a relatively short electric pulse can reseal themselves spontaneously and almost instantaneously after the removal of electric field. No significant damage to the cell is done in this case. Contrary to that, larger pores may become meta-stable with very long life time and cause irreversible damage. It can be said that, depending on the number, effective diameter -and life time of pores in the membrane, electroporation of the cell may result in significant metabolic or structural injury of the cell and/or its death. The cause of cell death after electroporation is believed to be an irreversible chemical imbalance and structural damage resulted from the fluid communication of the cytosol and the extracellular environment.
Below a certain limit of the electric field no pores are induced at all. This limit, usually referred to as the “lower EP limit” of electroporation, is different for different cells, depending, in part, on their sizes in an inverse relationship. That is, pores are induced in larger cells with smaller electric fields while smaller cells require larger electric fields. Above the lower EP limit the number of pores and their effective diameter increase with both the amplitude and duration of the electric field pulses.
Removing the electric field pulses enables the induced pores to reseal. This process of resealing of the pores and the ability of the cell to repair itself, discussed briefly above, currently is not well understood. The current understanding is that there is a significant range of electric field amplitudes and pulse durations in which cells survive electroporation and restore their viability thereafter. An electroporated cell may have open pores for as long as many minutes and still survive. The range of electric field amplitudes and pulse durations in which cells survive is successfully used in current biomedical practice for gene transfer and drug delivery inside living cells.
Nevertheless, the survivability of electroporated cells is limited As the electric field amplitude and/or duration of pulses, increases, this limit, usually referred to as the “upper EP limit” of electroporation, is inevitably achieved. Above the upper EP limit, the number and sizes of pores in the cellular membrane become too large for a cell to survive. Multiple pulses cause approximately the same effect on the cells as one pulse with a duration equal to the total duration of all applied pulses. After application of an electrical pulse above the upper electroporation limit the cell cannot repair itself by any spontaneous or biological process and dies. The upper EP limit is defined by the combinations of the amplitudes of electric field and pulse durations that cause cellular death.
The vulnerability of cells to electroporation depends on their size: the larger the cell, the lower the electric field and duration of a pulse capable of killing it. If cells of different sizes are exposed to the same electric field, the largest cells will die first. Thus, this ability of electroporation to discriminate cells by their sizes may be used to selectively kill large cells in the human body.
In the previously referred to application for U.S. patent application entitled “Apparatus and Method for Reducing Subcutaneous Fat Deposits, Virtual Face Lift and Body Sculpting by Electroporation”, Ser. No. 09/931,672, filed Aug. 17, 2001, an apparatus and method for performing non-invasive treatment of the human face and body by electroporation in lieu of cosmetic surgery is disclosed. The apparatus comprises a high voltage pulse generator and an applicator having two or more electrodes utilized in close mechanical and electrical proximity with the patient's skin to apply electrical pulses thereto. The applicator may include at least two electrodes with one electrode having a sharp tip and another having a flat surface. High voltage pulses delivered to the electrodes create at the tip of the sharp electrode an electric field high enough to cause death of relatively large subcutaneous fat cells by electroporation. Moving the electrode tip along the skin creates a line of dead subcutaneous fat cells, which later are metabolized by the body. Multiple applications of the electrode along predetermined lines on the face or neck create shrinkage of the skin and the subcutaneous fat reduction under the treated area.
The electroporation in-vivo, employed in the disclosed method is a non-invasive treatment of subcutaneous fat, which, as was previously described before, involves application of high amplitude electric pulses between external electrodes to cause death by electroporation of the subcutaneous fat cells. Fat cells, being typically larger than other cells of the body, are more easily killed by electroporation treatment than are smaller lean muscle cells. The electric field, applied to the external electrodes, is efficient for cell killing in the subcutaneous layer of fat tissue directly under the skin. However, the amplitude of the field significantly decreases with increasing the depth of the deposits of fat cells. The deeper penetration of the electric field may be achieved by increasing the distance between electrodes with simultaneous increase in the operating voltage. This approach, though, leads to concomitant increase of the volume that is treated by electroporation. Occasionally, during such cosmetic and body sculpting procedures as described above, a small volume of deep subcutaneous fat deposit must be treated. The non-invasive method of treating subcutaneous tissue by electroporation as described in the earlier referenced patent application, in which the high voltage pulses are applied to the external electrodes, is sometimes difficult to apply to deep fat deposits especially when a fine spatial resolution is required
It would be desirable to have available an apparatus and a method for electroporation treatment to reduce deep fat deposits by allowing deep localized application of the electroporation pulses that can provide high spatial resolution of the body sculpting. Preferably, such apparatus and methods would also be minimally invasive.
SUMMARY OF THE INVENTION
The present invention provides an apparatus and method for creation of a controlled electroporation injury to deep subcutaneous fat tissues that, with the healing that follows, leads to permanent loss of the fat cells in the treated tissue. According to present invention an electric field capable of killing fat cells in deep subcutaneous deposits may be applied by a set of needle electrodes, configured for placement deeply under the skin. An apparatus according to the current invention comprises a voltage pulse generator, an applicator with two or multiple electrodes of different shapes and sizes, and a cable connecting the electrodes to the pulse generator. The pulse generator produces a sequence of high voltage pulses of predetermined amplitude, duration and number to cause necrosis in a treated area of the subcutaneous tissue.
A method of weight loss and body sculpturing in accord with the present invention comprises application of electrical pulses to the electrodes positioned under the skin in a treatment area of the subcutaneous fat tissue. The amplitude, duration and number of applied pulses are selected to cause necrosis of fat cells at a predetermined distance around the needles in the subcutaneous tissue. During the treatment a number of sites in a predetermined pattern are exposed to electroporation. Later, during the healing process the treated area contracts as the electroporated cells die and are metabolized by the body, thus reducing volume of fat tissue and providing desired change of body contours. The injury to the tissues made by electroporation is very selective, targeting only large fat cell and not damaging the epidermis, the most external layer of the skin. As a matter of fact, in accordance with the current invention, the electrical field is applied only to the deep subcutaneous fat deposits, no electric field is applied to the skin of the patient.
The present invention, as well as its various features and advantages, will become evident to those skilled in the art when the following description of the invention is read in conjunction with the accompanying drawings as briefly described below and the appended claims. Throughout the drawings, like numerals refer to similar or identical parts.
DESCRIPTION OF THE DRAWINGS
FIG. 1 is a schematic illustration of an electroporation system for treatment of deep subcutaneous fat deposits.
FIG. 2 shows time diagrams for high voltage pulses during EP treatment wherein FIG. 2a illustrates unipolar pulsing and FIG. 2b illustrates bipolar pulsing.
FIG. 3 illustrates a one-needle applicator with two electrodes.
FIG. 4 illustrates an embodiment of an applicator comprising one needle in combination with an external patch electrode wherein FIG. 4a provides a plan view and FIG. 4b provides a cross-sectional view taken along viewing plane 4b—4b.
FIG. 5 illustrates an embodiment of the applicator comprising an array of needle electrodes.
FIG. 6 illustrates in orthogonal views in FIGS. 6a and 6b an embodiment of the applicator comprising needle electrodes without insulated parts.
DESCRIPTION OF THE INVENTION
FIG. 1 shows schematically an electroporation system 100 for in-vivo treatment of deep subcutaneous fat deposits. The system 100 includes a high voltage electroporation pulse generator 101 connected by an appropriate connector 102 to an applicator 103. Applicator 103 may include a handle 104 and a pair of needle 120 and 122 extending therefrom. Handle 104 may be used by the operator for the safe and efficacious placement of the needles 120 and 122 in a selected-for-treatment anatomical site. Needles 120 and 122 may include proximal insulated portions 124 and 126, respectively, central uninsulated portions 128 and 130, respectively, and distal insulated portions 132 and 134. Preferably, distal portions 132 and 134 includes sharpened ends or tips 136 and 138, respectively.
As illustrated in the Figure, an operator of system 100 will use handle 104 to push the tips 136 and 138 through the skin 150 of the patient into a deep subcutaneous fat deposit 152. The sharpened tips 136 and 138 facilitate penetration of the skin 150 and fat tissue 152 while minimizing pain or serious discomfort to the patient. Insulated proximal portions 124 and 126 of needles 120 and 122, respectively, provide electrical insulation from the skin 150 during an EP treatment. That is, this insulation prevents a current flow from the needles 120 and 122 through the skin and with it an associated discomfort of the patient. Similarly, the insulated distal portions 132 and 134 of needles 120 and 122 helps to avoid spark discharges between the tips during high voltage electroporation pulsing.
Central portions 128 and 130 form the electrodes for the system 10, which as noted are uninsulated. The electrodes 128 and 130 are in close electrical contact with the surrounding tissue 152 and provide a pulsed electrical field, as indicated by shown by arrows 160, to the treatment zone 162 between and around electrodes 128 and 130, as indicated by dotted line 162. It will be understood that the treatment zone is actually a three dimensional zone extending in all directions from the electrodes 128 and 130.
The larger the diameter of the cells or the higher applied voltage, the larger treatment zone 162 will be where the cells are actually killed. It should be mentioned that not all cells die at any point of the treatment zone. The smaller fat cells will survive. As was mentioned early, cell killing by electroporation is selective on the cell size and the upper EP limit is higher for small cells. Small fat cells, for which applied electric field is below the upper electroporation limit, will survive any reasonable number of electric pulses without any morphological or functional damage and will stay in the tissue. Also, there is no electroporation treatment for the tissues interfacing the insulated parts of the needles.
A computer 170 connected by an appropriate connector 172 to EP generator 101, may be provided to control the whole procedure of EP treatment: the predetermined amplitude, duration, and number of EP pulses supplied to the electrodes 128 and 130. The EP pulses may be applied with a repetition rate of about 1 to about 50 Hz and may have a current peak of about 0.5 to about 10 A depending on the size and shape of electrodes. Generally, the voltage of the EP pulses can be in the range of about 50 V to about 5000 V with a duration from about 10 microseconds to about 10.0 milliseconds depending on the location of the treated segment of the body, the sizes and shapes of the electrodes, and the distance between the electrodes. Regardless of the possible configuration of the electrodes and the voltages applied to the treatment volume, the voltage applied to an individual subcutaneous fat cell should fall in the range of about 2 to about 10 V per cell to be able to kill it.
To achieve successful cell killing by electroporation the electric field applied to the treated volume of cells must be above the upper EP limit for the cells. The probability of cell killing increases if longer or multiple pulses are employed.
According to present invention high voltage pulses of different waveforms may be used for the EP treatment. The pulses may be rectangular or exponential in shape, be unipolar (positive or negative only) or bipolar (positive and negative). Bipolar rectangular pulses are known to be very efficient in cell killing by electroporation. This is because both directions of the electrical field, positive and negative, are equally efficient in creating pores in cellular membranes, and the electric field strength, contrary to the exponential pulses, stays high during the whole pulse. The efficiency results because electroporation is a process related to the difference in the energy of the porous and non-porous membrane in the presence of an electric field. The energy difference depends on the square of the amplitude (or strength) of the electric field (i.e., E2) and does not depend on the sign or polarity (+ or −) of the electric field.
From a practical stand point, however, applying balanced pulses during in-vivo electroporation treatment has one important advantage. Contrary to unipolar pulsing, that carries a direct current component into the treated tissue and creates undesired electrolytic effects on the interface of the electrodes and tissues, bipolar pulsing is free from these drawbacks. With bipolar pulsing of the field, problems such as metal depositions from the electrodes or chemical decomposition of tissue during treatment are largely if not completely avoided.
These advantageous properties of balanced pulses, namely, high efficiency in cell killing and freedom from electrolytic effects, make using rectangular bipolar balanced pulses a preferred mode for electroporation pulsing in the current invention. Technically, balancing of two pulses of the opposite polarities may be easily achieved by using a pulse generator having a direct current blocking capacitor electrically coupled in series to the needle electrodes.
In FIGS. 2a and 2b plots of high voltage EP pulses against time are shown. In FIG. 2a the upper curve shows a plot of rectangular balanced pulses, the preferred embodiment and the lower curve shows exponential balanced pulses. FIG. 2b depicts rectangular and exponential unipolar pulses in the upper and lower curves, respectively.
In FIG. 3 another embodiment 300 of the needle applicator is shown. Needle applicator 300 comprises a single needle 310 with two axially separated electrodes 328 and 330 of opposite polarity insulated from each other and separated by insulator 308. The needle may be made of a hollow tube carrying inside two conductors connecting electrodes 328 and 330 via cable 302 to the output of the EP generator, not shown in the figure. Proximal end 325 of the needle 310 is covered with an insulation layer to protect the skin of the patient during treatment from an electric current and discomfort associated with it. To avoid sparking from the distal end 333 of the applicator the needle 310 may be made of insulating material or of a metal piece electrically insulated from the electrodes 328 and 330. Additionally, distal end 333 may have a sharp tip 337.
The electric field between electrodes 328 and 330 is shown by lines 360. Dotted lines 362 delineate the treatment zone, where the electric field is the highest and where actual killing cells by electroporation occurs.
Yet another embodiment 400 of the needle applicator is shown in FIG. 4 in two substantially orthogonal views, namely FIGS. 4a and 4b. Applicator 400 comprises a needle 410 with an electrode 428 combined with a patch electrode 430. Patch electrode 430 is placed on the skin 450 of the patient near the treatment site, which is delineated by a dotted line 462. Needle 410 may include a sharp tip 436 and insulated proximal and distal portions 442 and 433 on either side of electrode portion 428 of needle 410. The electrical field lines generated between electrodes 428 and 430 are indicated by lines 460. High voltage EP pulses during treatment are delivered to the electrodes 428 and 430 via appropriate conductors 454 and 455, respectively, which are connected to the connector 402 coupled to the output of the EP generator 101, not shown in the FIG. 4.
During use of the needle applicator 400, the electroporation leading to cellular death occurs only around the conductive surface, i.e., electrode 428, of the needle placed in the tissue. No electroporation takes place near the patch electrode 430 on the skin because the value of the electric field near its surface is less than the upper EP limit. FIG. 4b shows cross section of the applicator. Dotted line 462 delineates the treatment zone around the electrode 428 where the fat cells are killed.
FIG. 5 shows yet another implementation 500 of a needle applicator in accord with the present invention. Applicator 500 comprises a handle 504 supporting a needle frame 505. Needle frame 505 supports a plurality of needles 520 of one polarity (positive) and a plurality of needles 522 including an electrode of the other polarity (negative), with each needle of one polarity being adjacent to one or more needles of the other polarity. Handle 504 is connected via connector 502 to the output of the EP generator 101 (not shown in the Figure). The needles 520 and 522 in the needle array alternately have positive and negative polarity. The needles 520 and 522 may include a proximal insulated portion 524 and 526, central electrode portions 528 and 530, and distal insulated portions 536 and 538 respectively. Each needle 520 and 522 will also preferably include sharp tip 536 and 538. For EP treatment of subcutaneous deposits the needles are placed preferably normally to the skin. One of benefits of this configuration is that the tissue electroporation occurs in thin cylindrical layers around the electrodes and later, during healing process, macrophages from nearby blood vessels will travel a shorter distance to the damaged cells. Thus, this configuration may accelerate the disposal of the dead fat cells.
Yet another implementation of the needle applicator is shown in FIG. 6. Applicator 600 may include a handle 604 and a pair of needle 620 and 622 extending therefrom. Handle 604 may be used by the operator for the safe and efficacious placement of the needles 620 and 622 in a selected-for-treatment anatomical site. The sharpened tips 636 and 638 facilitate penetration of the skin 650 and fat tissue 652 while minimizing pain or serious discomfort to the patient. In this implementation of the current invention the whole needles 620 and 622 perform function of electrodes; that is, the needles 620 and 622 do not include insulated portions as in the previously described embodiments. Via an appropriate connector 602 needles 620 and 622 are connected to the EP generator (not shown in the Figures) providing high voltage pulses during treatment. Electric field lines between electrodes 620 and 622 are shown by arrows 660. Dotted line 662 shows the treatment area of the fat tissue 652 where electroporation actually kills fat cells.
Needle electrode diameters may fall in a range of about 0.3 mm to about 1.0 mm, which corresponds to the standard of minimally invasive size. The distance between adjacent needles may be in a range of several mm to several cm. Applied voltage, depending on the distance between needles and the size of the fat cells to be killed, may vary in a wide range from about 100 V to several hundreds and even thousands of volts. In any case the resultant electric field applied to the treated fat cells must be above their upper electroporation limit, or about 2 to about 10 V per cell. The electroporation pulses during treatment may be applied simultaneously to all electrodes or in a sequence of sets of two to several electrodes throughout the whole treated area. The number of pulses per treatment of a selected site may vary from several pulses to several tens of pulses. Preferred duration of the pulses is from about 10 microseconds to about 10 milliseconds.
A method for electroporation treatment of deep subcutaneous fat deposits comprises providing a high voltage pulse generator for generation EP pulses and a needle applicator. The needle applicator or needle applicator and pad electrode may be placed by a physician in an anatomically selected site of treatment under ultrasound or other type of imaging guidance. After the needle placement a sequence of high voltage EP pulses is applied to the electrodes. The electrodes may be placed in plurality of treatment sites in accordance with a treatment plan developed by a physician. Sequences of the high voltage EP pulses are repeatedly applied to the electrodes. After a session of electroporation treatment the remnants of fat cells and released lips will be metabolized and removed by the patient's body over about a two week period. A subsequent electroporation treatment can then be performed with new treatment sites selected for the electroporation treatment. In this manner, then, a patient's body can be sculpted as desired.
The present invention has been described in language more or less specific as to the apparatus and method features. It is to be understood, however, that the present invention is not limited to the specific features described, since the apparatus and method herein disclosed comprise exemplary forms of putting the present invention into effect. For example, while the needles have been described as having sharp tips, blunted end needles may also be used. Additionally, as indicated in the Figures, insulation may be used on the needles in some embodiments, but not others. The invention is, therefore, claimed in any of its forms or modifications within the proper scope of the appended claims appropriately interpreted in accordance with the doctrine of equivalency and other applicable judicial doctrines.

Claims (24)

1. An apparatus for reducing subcutaneous fat deposits by electroporation comprising:
an applicator comprising a plurality of needle electrodes adapted for penetrating the skin of a patient and applying a high amplitude pulsed electric field to the area of the subcutaneous volume of fat tissue to be treated by electroporation, at least one of said plurality of needle electrodes includes insulated portions and a pair of uninsulated needle portions axially separated along said needle electrode, wherein
said uninsulated needle portions form axially separate electrodes of opposite polarity; and
said insulated portions include proximal, distal, and central insulated portions, said proximal insulated portion being provided for insulating the skin of the patient during an electroporation treatment, said distal insulated portion being provided to avoid spark discharges to an adjacent needle electrode and said central insulated portion separating said electrodes, wherein said electrodes are disposed on said needle electrode such that they are disposed within the subcutaneous fat deposit during treatment;
a generator of high voltage pulses for applying pulsed electric field to the electrodes, said pulses generating an electric field above the upper electroporation limit for subcutaneous fat cells in the volume of subcutaneous fat tissue to be treated; and
connectors connecting said generator of high voltage electrical pulses with corresponding needle electrodes placed under the skin.
2. An apparatus according to claim 1 wherein said high voltage pulses have a duration in a range of about 10 microseconds to about 10 millisecond.
3. An apparatus according to claim 1 wherein the amplitude of the electric field applied to the treated volume falls in a range of about 20 Volt/mm to about 2000 Volt/mm.
4. An apparatus according to claim 1 wherein high voltage pulses are electrically balanced in such a manner that in average no direct current is passing through the treatment volume.
5. An apparatus according to claim 1 wherein high voltage pulses are rectangularly balanced.
6. A method for reducing deep subcutaneous fat deposits by electroporation comprising:
providing an applicator comprising a set of high voltage needle electrodes adapted for penetrating the skin of a patient and applying a high amplitude pulsed electric field to the area of the subcutaneous volume of tissues to be treated by electroporation, at least one of said plurality of needle electrodes including insulated portions and a pair of uninsulated needle portions axially separated along said needle electrode, wherein
said uninsulated needle portions form axially separated electrodes of opposite polarity; and
said insulated portions include proximal, distal, and central insulated portions, said proximal insulated portion being provided for insulating the skin of the patient during an electroporation treatment, said distal insulated portion being provided to avoid spark discharges to an adjacent needle electrode and said central insulated portion separating said electrodes, wherein said electrodes are disposed on said needle electrode such that they are disposed within the subcutaneous fat deposit during treatment;
providing a generator of high voltage pulses for applying pulsed electric field to the electrodes, said pulses generating an electric field above the upper electroporation limit for subcutaneous fat cells in the volume of the subcutaneous tissue to be treated;
connecting said generator of high voltage electrical pulses with corresponding needle electrodes placed in the deep subcutaneous fat tissue; and
applying high voltage pulses via said set of needle electrodes with an amplitude sufficient to cause death to subcutaneous fat cells.
7. An apparatus for reducing deep subcutaneous fat deposits in a predetermined treatment volume beneath a predetermined area of a patient's skin by electroporation, said apparatus comprising:
a set of needle electrodes, wherein said set of electrodes comprises:
an array of electroporation needle electrodes, said electroporation needle electrodes being provided for applying a pulsed electric field to the subcutaneous volume of tissues, wherein said needle electrodes are arrayed such that each needle electrode is adjacent to at least one needle electrode having the opposite polarity and wherein the needle electrodes include proximal and distal insulated portions and a central uninsulated portion configured to insulate the skin and dispose the uninsulated portion in the subcutaneous fat deposit;
a generator of high voltage pulses for applying a pulsed electric field to the predetermined area via said electrode set, said pulses generating an electric field above the upper electroporation limit for subcutaneous fat cells in the volume of the subcutaneous tissue to be treated, and
connectors connecting said generator of high voltage electrical pulses with corresponding electroporation electrodes.
8. An apparatus according to claim 7 wherein high voltage pulses are electrically balanced in such a manner that in average no direct current is passing through the treatment volume.
9. An apparatus according to claim 7 wherein high voltage pulses are rectangular rectangularly balanced.
10. Apparatus for reduction of subcutaneous fat deposits in a predetermined treatment zone beneath a predetermined area of a patient's skin by electroporation, said apparatus comprising:
a plurality of electrodes, wherein at least one of said electrodes is a subcutaneous electrode configured for placement under the skin and within the treatment zone and wherein at least one of said electrodes is a patch electrode applied to the patient's skin;
a generator of high voltage pulses for applying a pulsed electric field to the treatment zone via said electrodes, wherein the applied pulses generate an electric field above the upper electroporation limit for subcutaneous fat cells in the treatment zone, and
connectors connecting said generator of high voltage electrical pulses with said electrodes.
11. An apparatus according to claim 10 wherein said subcutaneous electrode is a needle electrode adapted for penetrating the skin of a patient, said needle electrode including insulated portions and a pair of uninsulated needle portions axially separated alone said needle electrode, wherein
said uninsulated needle portions form axially separate electrodes of opposite polarity; and
said insulated portions include proximal, distal, and central insulated portions, said proximal insulated portion being provided for insulating the skin of the patient during an electroporation treatment, said distal insulated portion being provided to avoid spark discharaes to an adjacent needle electrode and said central insulated portion separating said electrodes, wherein said electrodes are disposed on said needle electrode such that they are disposed within the subcutaneous fat deposit during treatment.
12. An apparatus according to claim 10 wherein said apparatus includes at least a pair of subcutaneous electrodes.
13. An apparatus according to claim 12 wherein each of said at least one pair of subcutaneous electrodes is formed on a needle comprising proximal and distal insulated portions and wherein said subcutaneous electrode is formed therebetween said insulated portions on each needle.
14. An apparatus according to claim 10 and further including plurality of subcutaneous electrodes and wherein said plurality of subcutaneous electrodes comprises an array of electrodes each configured for placement under the skin and within the treatment zone, said electrodes being provided with alternating positive and negative polarities.
15. An apparatus according to claim 10 wherein the high voltage pulses are electrically balanced in such a manner that in average no direct current is passing through the treatment zone.
16. An apparatus according to claim 10 wherein the high voltage pulses are rectangularly balanced.
17. An apparatus according to claim 10 wherein said high voltage pulses have a duration in a range of about 10 microseconds to about 10 millisecond.
18. A method for reducing the number of subcutaneous fat cells in a predetermined treatment zone by electroporation of the cells in the treatment zone, said method comprising:
disposing at least a first electrode in the treatment zone;
disposing a second electrode on the patient's skin in close proximity to the first electrode; and
applying high voltage electric field pulses via the first and second electrodes with an amplitude sufficient to cause death to subcutaneous fat cells by electroporation.
19. A method according to claim 18 wherein said at least one treatment zone electrode is a needle including an electrode.
20. A method according to claim 18 and further including a needle, wherein said plurality of electrodes comprises a pair of spaced apart electrodes disposed on said needle.
21. A method according to claim 18 wherein the high voltage pulses are electrically balanced in such a manner that in average no direct current is passing through the treatment zone.
22. An apparatus according to claim 17 wherein the amplitude of the electric field applied to the treated volume falls in a range of about 20 Volt/mm to about 2000 Volt/mm.
23. An apparatus according to claim 18 wherein said high voltage pulses have a duration in a range of about 10 microseconds to about 10 millisecond.
24. An apparatus according to claim 23 wherein the amplitude of the electric field applied to the treated volume falls in a range of about 20 Volt/mm to about 2000 Volt/mm.
US12/572,005 2000-08-17 2009-10-01 Apparatus and method for reducing subcutaneous fat deposits by electroporation Expired - Lifetime USRE43009E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/572,005 USRE43009E1 (en) 2000-08-17 2009-10-01 Apparatus and method for reducing subcutaneous fat deposits by electroporation

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US22577500P 2000-08-17 2000-08-17
US26710601P 2001-02-08 2001-02-08
US09/931,672 US6892099B2 (en) 2001-02-08 2001-08-17 Apparatus and method for reducing subcutaneous fat deposits, virtual face lift and body sculpturing by electroporation
US35844302P 2002-02-22 2002-02-22
US10/369,020 US6795728B2 (en) 2001-08-17 2003-02-19 Apparatus and method for reducing subcutaneous fat deposits by electroporation
US12/572,005 USRE43009E1 (en) 2000-08-17 2009-10-01 Apparatus and method for reducing subcutaneous fat deposits by electroporation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/369,020 Reissue US6795728B2 (en) 2000-08-17 2003-02-19 Apparatus and method for reducing subcutaneous fat deposits by electroporation

Publications (1)

Publication Number Publication Date
USRE43009E1 true USRE43009E1 (en) 2011-12-06

Family

ID=27669329

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/369,020 Ceased US6795728B2 (en) 2000-08-17 2003-02-19 Apparatus and method for reducing subcutaneous fat deposits by electroporation
US12/572,005 Expired - Lifetime USRE43009E1 (en) 2000-08-17 2009-10-01 Apparatus and method for reducing subcutaneous fat deposits by electroporation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/369,020 Ceased US6795728B2 (en) 2000-08-17 2003-02-19 Apparatus and method for reducing subcutaneous fat deposits by electroporation

Country Status (1)

Country Link
US (2) US6795728B2 (en)

Cited By (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8676338B2 (en) 2010-07-20 2014-03-18 Zeltiq Aesthetics, Inc. Combined modality treatment systems, methods and apparatus for body contouring applications
US8702774B2 (en) 2009-04-30 2014-04-22 Zeltiq Aesthetics, Inc. Device, system and method of removing heat from subcutaneous lipid-rich cells
US9314368B2 (en) 2010-01-25 2016-04-19 Zeltiq Aesthetics, Inc. Home-use applicators for non-invasively removing heat from subcutaneous lipid-rich cells via phase change coolants, and associates devices, systems and methods
US9375345B2 (en) 2006-09-26 2016-06-28 Zeltiq Aesthetics, Inc. Cooling device having a plurality of controllable cooling elements to provide a predetermined cooling profile
US9408745B2 (en) 2007-08-21 2016-08-09 Zeltiq Aesthetics, Inc. Monitoring the cooling of subcutaneous lipid-rich cells, such as the cooling of adipose tissue
US9545523B2 (en) 2013-03-14 2017-01-17 Zeltiq Aesthetics, Inc. Multi-modality treatment systems, methods and apparatus for altering subcutaneous lipid-rich tissue
USD777338S1 (en) 2014-03-20 2017-01-24 Zeltiq Aesthetics, Inc. Cryotherapy applicator for cooling tissue
US9598691B2 (en) 2008-04-29 2017-03-21 Virginia Tech Intellectual Properties, Inc. Irreversible electroporation to create tissue scaffolds
US9655770B2 (en) 2007-07-13 2017-05-23 Zeltiq Aesthetics, Inc. System for treating lipid-rich regions
US9737434B2 (en) 2008-12-17 2017-08-22 Zeltiq Aestehtics, Inc. Systems and methods with interrupt/resume capabilities for treating subcutaneous lipid-rich cells
US9757196B2 (en) 2011-09-28 2017-09-12 Angiodynamics, Inc. Multiple treatment zone ablation probe
US9844460B2 (en) 2013-03-14 2017-12-19 Zeltiq Aesthetics, Inc. Treatment systems with fluid mixing systems and fluid-cooled applicators and methods of using the same
US9861421B2 (en) 2014-01-31 2018-01-09 Zeltiq Aesthetics, Inc. Compositions, treatment systems and methods for improved cooling of lipid-rich tissue
US9867652B2 (en) 2008-04-29 2018-01-16 Virginia Tech Intellectual Properties, Inc. Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds
US9888956B2 (en) 2013-01-22 2018-02-13 Angiodynamics, Inc. Integrated pump and generator device and method of use
US9895189B2 (en) 2009-06-19 2018-02-20 Angiodynamics, Inc. Methods of sterilization and treating infection using irreversible electroporation
US10117707B2 (en) 2008-04-29 2018-11-06 Virginia Tech Intellectual Properties, Inc. System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies
US10154874B2 (en) 2008-04-29 2018-12-18 Virginia Tech Intellectual Properties, Inc. Immunotherapeutic methods using irreversible electroporation
US10238447B2 (en) 2008-04-29 2019-03-26 Virginia Tech Intellectual Properties, Inc. System and method for ablating a tissue site by electroporation with real-time monitoring of treatment progress
US10245105B2 (en) 2008-04-29 2019-04-02 Virginia Tech Intellectual Properties, Inc. Electroporation with cooling to treat tissue
US10272178B2 (en) 2008-04-29 2019-04-30 Virginia Tech Intellectual Properties Inc. Methods for blood-brain barrier disruption using electrical energy
US10292755B2 (en) 2009-04-09 2019-05-21 Virginia Tech Intellectual Properties, Inc. High frequency electroporation for cancer therapy
US10383787B2 (en) 2007-05-18 2019-08-20 Zeltiq Aesthetics, Inc. Treatment apparatus for removing heat from subcutaneous lipid-rich cells and massaging tissue
US10470822B2 (en) 2008-04-29 2019-11-12 Virginia Tech Intellectual Properties, Inc. System and method for estimating a treatment volume for administering electrical-energy based therapies
US10471254B2 (en) 2014-05-12 2019-11-12 Virginia Tech Intellectual Properties, Inc. Selective modulation of intracellular effects of cells using pulsed electric fields
US10524956B2 (en) 2016-01-07 2020-01-07 Zeltiq Aesthetics, Inc. Temperature-dependent adhesion between applicator and skin during cooling of tissue
US10555831B2 (en) 2016-05-10 2020-02-11 Zeltiq Aesthetics, Inc. Hydrogel substances and methods of cryotherapy
US10568759B2 (en) 2014-08-19 2020-02-25 Zeltiq Aesthetics, Inc. Treatment systems, small volume applicators, and methods for treating submental tissue
US10675176B1 (en) 2014-03-19 2020-06-09 Zeltiq Aesthetics, Inc. Treatment systems, devices, and methods for cooling targeted tissue
US10682297B2 (en) 2016-05-10 2020-06-16 Zeltiq Aesthetics, Inc. Liposomes, emulsions, and methods for cryotherapy
US10694972B2 (en) 2014-12-15 2020-06-30 Virginia Tech Intellectual Properties, Inc. Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment
US10702326B2 (en) 2011-07-15 2020-07-07 Virginia Tech Intellectual Properties, Inc. Device and method for electroporation based treatment of stenosis of a tubular body part
US10702337B2 (en) 2016-06-27 2020-07-07 Galary, Inc. Methods, apparatuses, and systems for the treatment of pulmonary disorders
US10765552B2 (en) 2016-02-18 2020-09-08 Zeltiq Aesthetics, Inc. Cooling cup applicators with contoured heads and liner assemblies
US10935174B2 (en) 2014-08-19 2021-03-02 Zeltiq Aesthetics, Inc. Stress relief couplings for cryotherapy apparatuses
US10952891B1 (en) 2014-05-13 2021-03-23 Zeltiq Aesthetics, Inc. Treatment systems with adjustable gap applicators and methods for cooling tissue
US11076879B2 (en) 2017-04-26 2021-08-03 Zeltiq Aesthetics, Inc. Shallow surface cryotherapy applicators and related technology
US11154418B2 (en) 2015-10-19 2021-10-26 Zeltiq Aesthetics, Inc. Vascular treatment systems, cooling devices, and methods for cooling vascular structures
US11254926B2 (en) 2008-04-29 2022-02-22 Virginia Tech Intellectual Properties, Inc. Devices and methods for high frequency electroporation
US11272979B2 (en) 2008-04-29 2022-03-15 Virginia Tech Intellectual Properties, Inc. System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies
US11311329B2 (en) 2018-03-13 2022-04-26 Virginia Tech Intellectual Properties, Inc. Treatment planning for immunotherapy based treatments using non-thermal ablation techniques
US11382681B2 (en) 2009-04-09 2022-07-12 Virginia Tech Intellectual Properties, Inc. Device and methods for delivery of high frequency electrical pulses for non-thermal ablation
US11382790B2 (en) 2016-05-10 2022-07-12 Zeltiq Aesthetics, Inc. Skin freezing systems for treating acne and skin conditions
US11395760B2 (en) 2006-09-26 2022-07-26 Zeltiq Aesthetics, Inc. Tissue treatment methods
US11446175B2 (en) 2018-07-31 2022-09-20 Zeltiq Aesthetics, Inc. Methods, devices, and systems for improving skin characteristics
US11453873B2 (en) 2008-04-29 2022-09-27 Virginia Tech Intellectual Properties, Inc. Methods for delivery of biphasic electrical pulses for non-thermal ablation
US11607537B2 (en) 2017-12-05 2023-03-21 Virginia Tech Intellectual Properties, Inc. Method for treating neurological disorders, including tumors, with electroporation
US11638603B2 (en) 2009-04-09 2023-05-02 Virginia Tech Intellectual Properties, Inc. Selective modulation of intracellular effects of cells using pulsed electric fields
US11707629B2 (en) 2009-05-28 2023-07-25 Angiodynamics, Inc. System and method for synchronizing energy delivery to the cardiac rhythm
US11723710B2 (en) 2016-11-17 2023-08-15 Angiodynamics, Inc. Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode
US11925405B2 (en) 2018-03-13 2024-03-12 Virginia Tech Intellectual Properties, Inc. Treatment planning system for immunotherapy enhancement via non-thermal ablation
US11931096B2 (en) 2010-10-13 2024-03-19 Angiodynamics, Inc. System and method for electrically ablating tissue of a patient
US11950835B2 (en) 2019-06-28 2024-04-09 Virginia Tech Intellectual Properties, Inc. Cycled pulsing to mitigate thermal damage for multi-electrode irreversible electroporation therapy
US11986421B2 (en) 2006-09-26 2024-05-21 Zeltiq Aesthetics, Inc. Cooling devices with flexible sensors
US12070411B2 (en) 2006-04-28 2024-08-27 Zeltiq Aesthetics, Inc. Cryoprotectant for use with a treatment device for improved cooling of subcutaneous lipid-rich cells
US12102376B2 (en) 2012-02-08 2024-10-01 Angiodynamics, Inc. System and method for increasing a target zone for electrical ablation
US12114911B2 (en) 2014-08-28 2024-10-15 Angiodynamics, Inc. System and method for ablating a tissue site by electroporation with real-time pulse monitoring

Families Citing this family (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6300108B1 (en) 1999-07-21 2001-10-09 The Regents Of The University Of California Controlled electroporation and mass transfer across cell membranes
US6892099B2 (en) 2001-02-08 2005-05-10 Minnesota Medical Physics, Llc Apparatus and method for reducing subcutaneous fat deposits, virtual face lift and body sculpturing by electroporation
US6795728B2 (en) 2001-08-17 2004-09-21 Minnesota Medical Physics, Llc Apparatus and method for reducing subcutaneous fat deposits by electroporation
US6697670B2 (en) * 2001-08-17 2004-02-24 Minnesota Medical Physics, Llc Apparatus and method for reducing subcutaneous fat deposits by electroporation with improved comfort of patients
US8251986B2 (en) 2000-08-17 2012-08-28 Angiodynamics, Inc. Method of destroying tissue cells by eletroporation
USRE42016E1 (en) 2001-08-13 2010-12-28 Angiodynamics, Inc. Apparatus and method for the treatment of benign prostatic hyperplasia
US7130697B2 (en) * 2002-08-13 2006-10-31 Minnesota Medical Physics Llc Apparatus and method for the treatment of benign prostatic hyperplasia
US6994706B2 (en) 2001-08-13 2006-02-07 Minnesota Medical Physics, Llc Apparatus and method for treatment of benign prostatic hyperplasia
US8150519B2 (en) 2002-04-08 2012-04-03 Ardian, Inc. Methods and apparatus for bilateral renal neuromodulation
US9308044B2 (en) 2002-04-08 2016-04-12 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation
US8774922B2 (en) 2002-04-08 2014-07-08 Medtronic Ardian Luxembourg S.A.R.L. Catheter apparatuses having expandable balloons for renal neuromodulation and associated systems and methods
US20080213331A1 (en) 2002-04-08 2008-09-04 Ardian, Inc. Methods and devices for renal nerve blocking
US7853333B2 (en) 2002-04-08 2010-12-14 Ardian, Inc. Methods and apparatus for multi-vessel renal neuromodulation
US6978174B2 (en) 2002-04-08 2005-12-20 Ardian, Inc. Methods and devices for renal nerve blocking
US7617005B2 (en) 2002-04-08 2009-11-10 Ardian, Inc. Methods and apparatus for thermally-induced renal neuromodulation
US9308043B2 (en) 2002-04-08 2016-04-12 Medtronic Ardian Luxembourg S.A.R.L. Methods for monopolar renal neuromodulation
US7620451B2 (en) 2005-12-29 2009-11-17 Ardian, Inc. Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach
US8131371B2 (en) 2002-04-08 2012-03-06 Ardian, Inc. Methods and apparatus for monopolar renal neuromodulation
US8175711B2 (en) 2002-04-08 2012-05-08 Ardian, Inc. Methods for treating a condition or disease associated with cardio-renal function
US8347891B2 (en) 2002-04-08 2013-01-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen
US8145317B2 (en) 2002-04-08 2012-03-27 Ardian, Inc. Methods for renal neuromodulation
US20070129761A1 (en) 2002-04-08 2007-06-07 Ardian, Inc. Methods for treating heart arrhythmia
US8145316B2 (en) 2002-04-08 2012-03-27 Ardian, Inc. Methods and apparatus for renal neuromodulation
US8774913B2 (en) 2002-04-08 2014-07-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for intravasculary-induced neuromodulation
US20140018880A1 (en) 2002-04-08 2014-01-16 Medtronic Ardian Luxembourg S.A.R.L. Methods for monopolar renal neuromodulation
US7756583B2 (en) 2002-04-08 2010-07-13 Ardian, Inc. Methods and apparatus for intravascularly-induced neuromodulation
US20070135875A1 (en) 2002-04-08 2007-06-14 Ardian, Inc. Methods and apparatus for thermally-induced renal neuromodulation
US7162303B2 (en) 2002-04-08 2007-01-09 Ardian, Inc. Renal nerve stimulation method and apparatus for treatment of patients
US7653438B2 (en) 2002-04-08 2010-01-26 Ardian, Inc. Methods and apparatus for renal neuromodulation
US9636174B2 (en) 2002-04-08 2017-05-02 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation
AU2003223351A1 (en) * 2002-04-16 2003-11-03 Cyto Pulse Sciences, Inc. Method of treating biological materials with translating electrical fields and electrode polarity reversal
US8298222B2 (en) 2003-12-24 2012-10-30 The Regents Of The University Of California Electroporation to deliver chemotherapeutics and enhance tumor regression
AU2004311842C1 (en) 2003-12-24 2011-01-06 The Regents Of The University Of California Tissue ablation with irreversible electroporation
EP1742588B1 (en) 2004-04-01 2016-10-19 The General Hospital Corporation Apparatus for dermatological treatment and tissue reshaping
US20060047281A1 (en) * 2004-09-01 2006-03-02 Syneron Medical Ltd. Method and system for invasive skin treatment
US7937143B2 (en) 2004-11-02 2011-05-03 Ardian, Inc. Methods and apparatus for inducing controlled renal neuromodulation
GB2423020A (en) * 2005-02-14 2006-08-16 Algotec Ltd Percutaneous electrical stimulation probe for pain relief
US20120226271A1 (en) * 2005-03-25 2012-09-06 Peter Callas Vacuum Ablation Apparatus and Method
US8114070B2 (en) * 2005-06-24 2012-02-14 Angiodynamics, Inc. Methods and systems for treating BPH using electroporation
US20060293725A1 (en) * 2005-06-24 2006-12-28 Boris Rubinsky Methods and systems for treating fatty tissue sites using electroporation
US20060293731A1 (en) * 2005-06-24 2006-12-28 Boris Rubinsky Methods and systems for treating tumors using electroporation
US20060293730A1 (en) 2005-06-24 2006-12-28 Boris Rubinsky Methods and systems for treating restenosis sites using electroporation
US9011473B2 (en) 2005-09-07 2015-04-21 Ulthera, Inc. Dissection handpiece and method for reducing the appearance of cellulite
JP2009506873A (en) * 2005-09-07 2009-02-19 ザ ファウンドリー, インコーポレイテッド Apparatus and method for disrupting subcutaneous structures
US9358033B2 (en) 2005-09-07 2016-06-07 Ulthera, Inc. Fluid-jet dissection system and method for reducing the appearance of cellulite
US9486274B2 (en) 2005-09-07 2016-11-08 Ulthera, Inc. Dissection handpiece and method for reducing the appearance of cellulite
US10548659B2 (en) 2006-01-17 2020-02-04 Ulthera, Inc. High pressure pre-burst for improved fluid delivery
US8518069B2 (en) 2005-09-07 2013-08-27 Cabochon Aesthetics, Inc. Dissection handpiece and method for reducing the appearance of cellulite
US7967763B2 (en) 2005-09-07 2011-06-28 Cabochon Aesthetics, Inc. Method for treating subcutaneous tissues
US8430863B2 (en) * 2005-12-02 2013-04-30 Abbott Cardiovascular Systems Inc. Visualization of a catheter viewed under ultrasound imaging
US7885793B2 (en) 2007-05-22 2011-02-08 International Business Machines Corporation Method and system for developing a conceptual model to facilitate generating a business-aligned information technology solution
US9248317B2 (en) 2005-12-02 2016-02-02 Ulthera, Inc. Devices and methods for selectively lysing cells
BRPI0620895B8 (en) * 2006-01-03 2021-06-22 Alcon Inc system for breaking connections that hold portions of soft tissue together
CN101534734B (en) * 2006-07-05 2012-08-08 博维医药公司 Apparatus and method for skin tightening and corrective forming
EP2076313A4 (en) * 2006-10-16 2012-07-25 Univ California Gels with predetermined conductivity used in irreversible electroporation of tissue
US20080132884A1 (en) * 2006-12-01 2008-06-05 Boris Rubinsky Systems for treating tissue sites using electroporation
US7655004B2 (en) 2007-02-15 2010-02-02 Ethicon Endo-Surgery, Inc. Electroporation ablation apparatus, system, and method
US8075572B2 (en) 2007-04-26 2011-12-13 Ethicon Endo-Surgery, Inc. Surgical suturing apparatus
US8100922B2 (en) 2007-04-27 2012-01-24 Ethicon Endo-Surgery, Inc. Curved needle suturing tool
US20080312648A1 (en) * 2007-06-12 2008-12-18 Darion Peterson Fat removal and sculpting device
US8103355B2 (en) * 2007-07-16 2012-01-24 Invasix Ltd Method and device for minimally invasive skin and fat treatment
US8579897B2 (en) 2007-11-21 2013-11-12 Ethicon Endo-Surgery, Inc. Bipolar forceps
US8262655B2 (en) 2007-11-21 2012-09-11 Ethicon Endo-Surgery, Inc. Bipolar forceps
US8568410B2 (en) 2007-08-31 2013-10-29 Ethicon Endo-Surgery, Inc. Electrical ablation surgical instruments
US8439940B2 (en) 2010-12-22 2013-05-14 Cabochon Aesthetics, Inc. Dissection handpiece with aspiration means for reducing the appearance of cellulite
US8480657B2 (en) 2007-10-31 2013-07-09 Ethicon Endo-Surgery, Inc. Detachable distal overtube section and methods for forming a sealable opening in the wall of an organ
US20090112059A1 (en) 2007-10-31 2009-04-30 Nobis Rudolph H Apparatus and methods for closing a gastrotomy
KR101626167B1 (en) 2008-01-17 2016-05-31 시네론 메디컬 리미티드 A hair removal apparatus for personal use and the method of using same
US8262680B2 (en) 2008-03-10 2012-09-11 Ethicon Endo-Surgery, Inc. Anastomotic device
US7806002B2 (en) * 2008-03-25 2010-10-05 Lear Corporation Capacitive sensing in an automotive mirror
US20090247933A1 (en) 2008-03-27 2009-10-01 The Regents Of The University Of California; Angiodynamics, Inc. Balloon catheter method for reducing restenosis via irreversible electroporation
US8682426B2 (en) * 2008-04-07 2014-03-25 Old Dominion Research Foundation Delivery device, system, and method for delivering nanosecond pulsed electric fields
US8926606B2 (en) 2009-04-09 2015-01-06 Virginia Tech Intellectual Properties, Inc. Integration of very short electric pulses for minimally to noninvasive electroporation
US8348938B2 (en) 2008-05-06 2013-01-08 Old Dominian University Research Foundation Apparatus, systems and methods for treating a human tissue condition
WO2009137800A2 (en) 2008-05-09 2009-11-12 Angiodynamics, Inc. Electroporation device and method
US8652150B2 (en) 2008-05-30 2014-02-18 Ethicon Endo-Surgery, Inc. Multifunction surgical device
US8070759B2 (en) 2008-05-30 2011-12-06 Ethicon Endo-Surgery, Inc. Surgical fastening device
US8771260B2 (en) 2008-05-30 2014-07-08 Ethicon Endo-Surgery, Inc. Actuating and articulating surgical device
US8114072B2 (en) 2008-05-30 2012-02-14 Ethicon Endo-Surgery, Inc. Electrical ablation device
US8317806B2 (en) 2008-05-30 2012-11-27 Ethicon Endo-Surgery, Inc. Endoscopic suturing tension controlling and indication devices
US8679003B2 (en) 2008-05-30 2014-03-25 Ethicon Endo-Surgery, Inc. Surgical device and endoscope including same
US8906035B2 (en) 2008-06-04 2014-12-09 Ethicon Endo-Surgery, Inc. Endoscopic drop off bag
US8403926B2 (en) 2008-06-05 2013-03-26 Ethicon Endo-Surgery, Inc. Manually articulating devices
US9173704B2 (en) 2008-06-20 2015-11-03 Angiodynamics, Inc. Device and method for the ablation of fibrin sheath formation on a venous catheter
WO2010008834A2 (en) 2008-06-23 2010-01-21 Angiodynamics, Inc. Treatment devices and methods
US8361112B2 (en) 2008-06-27 2013-01-29 Ethicon Endo-Surgery, Inc. Surgical suture arrangement
US8888792B2 (en) 2008-07-14 2014-11-18 Ethicon Endo-Surgery, Inc. Tissue apposition clip application devices and methods
US8262563B2 (en) 2008-07-14 2012-09-11 Ethicon Endo-Surgery, Inc. Endoscopic translumenal articulatable steerable overtube
US20100017750A1 (en) 2008-07-16 2010-01-21 Avner Rosenberg User interface
US9314293B2 (en) 2008-07-16 2016-04-19 Syneron Medical Ltd RF electrode for aesthetic and body shaping devices and method of using same
US8211125B2 (en) 2008-08-15 2012-07-03 Ethicon Endo-Surgery, Inc. Sterile appliance delivery device for endoscopic procedures
US8529563B2 (en) * 2008-08-25 2013-09-10 Ethicon Endo-Surgery, Inc. Electrical ablation devices
US8241204B2 (en) 2008-08-29 2012-08-14 Ethicon Endo-Surgery, Inc. Articulating end cap
US8480689B2 (en) 2008-09-02 2013-07-09 Ethicon Endo-Surgery, Inc. Suturing device
US8409200B2 (en) 2008-09-03 2013-04-02 Ethicon Endo-Surgery, Inc. Surgical grasping device
US8114119B2 (en) 2008-09-09 2012-02-14 Ethicon Endo-Surgery, Inc. Surgical grasping device
US8337394B2 (en) 2008-10-01 2012-12-25 Ethicon Endo-Surgery, Inc. Overtube with expandable tip
US8157834B2 (en) 2008-11-25 2012-04-17 Ethicon Endo-Surgery, Inc. Rotational coupling device for surgical instrument with flexible actuators
US8172772B2 (en) 2008-12-11 2012-05-08 Ethicon Endo-Surgery, Inc. Specimen retrieval device
US8652129B2 (en) 2008-12-31 2014-02-18 Medtronic Ardian Luxembourg S.A.R.L. Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation
US8828031B2 (en) 2009-01-12 2014-09-09 Ethicon Endo-Surgery, Inc. Apparatus for forming an anastomosis
US8361066B2 (en) 2009-01-12 2013-01-29 Ethicon Endo-Surgery, Inc. Electrical ablation devices
US8753335B2 (en) 2009-01-23 2014-06-17 Angiodynamics, Inc. Therapeutic energy delivery device with rotational mechanism
US9226772B2 (en) 2009-01-30 2016-01-05 Ethicon Endo-Surgery, Inc. Surgical device
US8252057B2 (en) 2009-01-30 2012-08-28 Ethicon Endo-Surgery, Inc. Surgical access device
US8037591B2 (en) 2009-02-02 2011-10-18 Ethicon Endo-Surgery, Inc. Surgical scissors
US8231603B2 (en) 2009-02-10 2012-07-31 Angiodynamics, Inc. Irreversible electroporation and tissue regeneration
US8606366B2 (en) 2009-02-18 2013-12-10 Syneron Medical Ltd. Skin treatment apparatus for personal use and method for using same
ES2461619T3 (en) 2009-02-25 2014-05-20 Syneron Medical Ltd. Electric skin rejuvenation
US8167280B2 (en) * 2009-03-23 2012-05-01 Cabochon Aesthetics, Inc. Bubble generator having disposable bubble cartridges
US20100249772A1 (en) * 2009-03-26 2010-09-30 Primaeva Medical, Inc. Treatment of skin deformation
US20100249700A1 (en) * 2009-03-27 2010-09-30 Ethicon Endo-Surgery, Inc. Surgical instruments for in vivo assembly
US8632534B2 (en) * 2009-04-03 2014-01-21 Angiodynamics, Inc. Irreversible electroporation (IRE) for congestive obstructive pulmonary disease (COPD)
WO2010120847A1 (en) * 2009-04-14 2010-10-21 Old Dominion University Research Foundation System and method for applying plasma sparks to tissue
USD630321S1 (en) 2009-05-08 2011-01-04 Angio Dynamics, Inc. Probe handle
US20100298825A1 (en) * 2009-05-08 2010-11-25 Cellutions, Inc. Treatment System With A Pulse Forming Network For Achieving Plasma In Tissue
US20110213336A1 (en) 2009-08-05 2011-09-01 Cucin Robert L Method of and apparatus for sampling, processing and collecting tissue and reinjecting the same into human patients
US8465471B2 (en) 2009-08-05 2013-06-18 Rocin Laboratories, Inc. Endoscopically-guided electro-cauterizing power-assisted fat aspiration system for aspirating visceral fat tissue within the abdomen of a patient
US8348929B2 (en) * 2009-08-05 2013-01-08 Rocin Laboratories, Inc. Endoscopically-guided tissue aspiration system for safely removing fat tissue from a patient
US9358064B2 (en) 2009-08-07 2016-06-07 Ulthera, Inc. Handpiece and methods for performing subcutaneous surgery
US11096708B2 (en) 2009-08-07 2021-08-24 Ulthera, Inc. Devices and methods for performing subcutaneous surgery
US20110098704A1 (en) 2009-10-28 2011-04-28 Ethicon Endo-Surgery, Inc. Electrical ablation devices
US8608652B2 (en) 2009-11-05 2013-12-17 Ethicon Endo-Surgery, Inc. Vaginal entry surgical devices, kit, system, and method
US20110118729A1 (en) * 2009-11-13 2011-05-19 Alcon Research, Ltd High-intensity pulsed electric field vitrectomy apparatus with load detection
US20110118732A1 (en) 2009-11-19 2011-05-19 The Regents Of The University Of California Controlled irreversible electroporation
JP5701895B2 (en) 2009-12-06 2015-04-15 シネロン メディカル リミテッド Method and apparatus for personal skin treatment
US20110135626A1 (en) * 2009-12-08 2011-06-09 Alcon Research, Ltd. Localized Chemical Lysis of Ocular Tissue
US20110144562A1 (en) * 2009-12-14 2011-06-16 Alcon Research, Ltd. Localized Pharmacological Treatment of Ocular Tissue Using High-Intensity Pulsed Electrical Fields
US20110144638A1 (en) * 2009-12-14 2011-06-16 Alcon Research, Ltd. Localized Shockwave-Induced Tissue Disruption
US8353487B2 (en) 2009-12-17 2013-01-15 Ethicon Endo-Surgery, Inc. User interface support devices for endoscopic surgical instruments
US8496574B2 (en) 2009-12-17 2013-07-30 Ethicon Endo-Surgery, Inc. Selectively positionable camera for surgical guide tube assembly
US9028483B2 (en) 2009-12-18 2015-05-12 Ethicon Endo-Surgery, Inc. Surgical instrument comprising an electrode
US8506564B2 (en) 2009-12-18 2013-08-13 Ethicon Endo-Surgery, Inc. Surgical instrument comprising an electrode
US9005198B2 (en) 2010-01-29 2015-04-14 Ethicon Endo-Surgery, Inc. Surgical instrument comprising an electrode
AT11956U1 (en) * 2010-06-30 2011-08-15 Biegler Gmbh ELECTRICAL STIMULATION DEVICE
US8546979B2 (en) 2010-08-11 2013-10-01 Alcon Research, Ltd. Self-matching pulse generator with adjustable pulse width and pulse frequency
US8652130B2 (en) 2010-08-18 2014-02-18 Invasix Ltd. Method and device for soft tissue ablation
US9872721B2 (en) * 2010-09-09 2018-01-23 Old Dominion University Research Foundation Multi-electrode electrical pulse delivery system for treatment of biological tissues
CN103313671B (en) 2010-10-25 2017-06-06 美敦力Af卢森堡有限责任公司 Device, the system and method for estimation and feedback for nerve modulation treatment
US10092291B2 (en) 2011-01-25 2018-10-09 Ethicon Endo-Surgery, Inc. Surgical instrument with selectively rigidizable features
US20120220813A1 (en) * 2011-01-25 2012-08-30 Sanford Lane Devices and methods for applying energy to a muscular layer
AU2012211041A1 (en) * 2011-01-28 2013-08-15 Kambouris Shares Pty Ltd An electrode for subcutaneous electolipolysis
US9233241B2 (en) 2011-02-28 2016-01-12 Ethicon Endo-Surgery, Inc. Electrical ablation devices and methods
US9254169B2 (en) * 2011-02-28 2016-02-09 Ethicon Endo-Surgery, Inc. Electrical ablation devices and methods
US9314620B2 (en) 2011-02-28 2016-04-19 Ethicon Endo-Surgery, Inc. Electrical ablation devices and methods
US9049987B2 (en) 2011-03-17 2015-06-09 Ethicon Endo-Surgery, Inc. Hand held surgical device for manipulating an internal magnet assembly within a patient
US9457183B2 (en) 2011-06-15 2016-10-04 Tripep Ab Injection needle and device
HUE042454T2 (en) * 2011-07-21 2019-07-29 Massachusetts Gen Hospital Apparatus for damage and removal of fat
US8986199B2 (en) 2012-02-17 2015-03-24 Ethicon Endo-Surgery, Inc. Apparatus and methods for cleaning the lens of an endoscope
JP6195856B2 (en) 2012-03-08 2017-09-13 メドトロニック アーディアン ルクセンブルク ソシエテ ア レスポンサビリテ リミテ Biomarker sampling and related systems and methods for neuromodulators
WO2013134548A2 (en) 2012-03-08 2013-09-12 Medtronic Ardian Luxembourg S.A.R.L. Ovarian neuromodulation and associated systems and methods
US9427255B2 (en) 2012-05-14 2016-08-30 Ethicon Endo-Surgery, Inc. Apparatus for introducing a steerable camera assembly into a patient
US9078662B2 (en) 2012-07-03 2015-07-14 Ethicon Endo-Surgery, Inc. Endoscopic cap electrode and method for using the same
US9545290B2 (en) 2012-07-30 2017-01-17 Ethicon Endo-Surgery, Inc. Needle probe guide
US10314649B2 (en) 2012-08-02 2019-06-11 Ethicon Endo-Surgery, Inc. Flexible expandable electrode and method of intraluminal delivery of pulsed power
US9572623B2 (en) 2012-08-02 2017-02-21 Ethicon Endo-Surgery, Inc. Reusable electrode and disposable sheath
US9277957B2 (en) 2012-08-15 2016-03-08 Ethicon Endo-Surgery, Inc. Electrosurgical devices and methods
US20140110296A1 (en) 2012-10-19 2014-04-24 Medtronic Ardian Luxembourg S.A.R.L. Packaging for Catheter Treatment Devices and Associated Devices, Systems, and Methods
US10183163B2 (en) * 2012-12-27 2019-01-22 The General Hospital Corporation Systems and methods for delivering pulsed electric fields to skin tissue
EP4039236A1 (en) 2013-02-20 2022-08-10 Cytrellis Biosystems, Inc. System for tightening a region of skin
US10098527B2 (en) 2013-02-27 2018-10-16 Ethidcon Endo-Surgery, Inc. System for performing a minimally invasive surgical procedure
AU2014360318B2 (en) 2013-12-05 2019-10-31 Rfemb Holdings, Llc Cancer immunotherapy by radiofrequency electrical membrane breakdown (RF-EMB)
US10166321B2 (en) 2014-01-09 2019-01-01 Angiodynamics, Inc. High-flow port and infusion needle systems
US9918790B2 (en) * 2014-01-23 2018-03-20 Old Dominion University Research Foundation Ablation of myocardial tissues with nanosecond pulsed electric fields
US9980766B1 (en) 2014-03-28 2018-05-29 Medtronic Ardian Luxembourg S.A.R.L. Methods and systems for renal neuromodulation
US10194979B1 (en) 2014-03-28 2019-02-05 Medtronic Ardian Luxembourg S.A.R.L. Methods for catheter-based renal neuromodulation
US10194980B1 (en) 2014-03-28 2019-02-05 Medtronic Ardian Luxembourg S.A.R.L. Methods for catheter-based renal neuromodulation
US11324534B2 (en) 2014-11-14 2022-05-10 Cytrellis Biosystems, Inc. Devices and methods for ablation of the skin
JP6723249B2 (en) 2015-01-30 2020-07-15 アールエフイーエムビー ホールディングス リミテッド ライアビリティ カンパニー System and method for ablating soft tissue
US10660691B2 (en) 2015-10-07 2020-05-26 Angiodynamics, Inc. Multiple use subassembly with integrated fluid delivery system for use with single or dual-lumen peristaltic tubing
CN109069624A (en) 2016-01-15 2018-12-21 瑞美控股有限责任公司 The immunization therapy of cancer
CA3018976A1 (en) 2016-03-29 2017-10-05 Cytrellis Biosystems, Inc. Devices and methods for cosmetic skin resurfacing
CN106110501A (en) * 2016-09-14 2016-11-16 合肥京东方光电科技有限公司 Transcutaneous electric nerve stimulation electrode needle, transcutaneous electric nerve stimulation device
US11464954B2 (en) 2016-09-21 2022-10-11 Cytrellis Biosystems, Inc. Devices and methods for cosmetic skin resurfacing
CA3096494A1 (en) * 2018-04-26 2020-02-20 Innovative Health Solutions, Inc. Auricular nerve field stimulation device
BR102019013578A2 (en) * 2019-06-28 2021-01-05 Eqt Equipamentos E Tecnologia Ltda. ELECTROPORATION APPLICATOR TIP FOR ELECTROCHEMOTHERAPY PROCEDURE
PE20221815A1 (en) * 2020-03-20 2022-11-29 Inovio Pharmaceuticals Inc VACUUM ASSISTED ELECTROPORATION DEVICES AND RELATED SYSTEMS AND METHODS

Citations (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1653819A (en) 1926-08-07 1927-12-27 Northcott Ephraim Electrotherapeutical apparatus
DE863111C (en) 1951-07-03 1953-01-15 Walter Hallegger Instrument for transcutaneous and subcutaneous heating and iontophoresis and method of its use
US4016886A (en) 1974-11-26 1977-04-12 The United States Of America As Represented By The United States Energy Research And Development Administration Method for localizing heating in tumor tissue
US4226246A (en) 1977-05-27 1980-10-07 Carba Societe Anonyme Apparatus for maintaining the negative potential of human, animal, and plant cells
US4262672A (en) 1978-01-02 1981-04-21 Horst Kief Acupuncture instrument
US4407943A (en) 1976-12-16 1983-10-04 Millipore Corporation Immobilized antibody or antigen for immunoassay
US4810963A (en) 1984-04-03 1989-03-07 Public Health Laboratory Service Board Method for investigating the condition of a bacterial suspension through frequency profile of electrical admittance
US4907601A (en) 1988-06-15 1990-03-13 Etama Ag Electrotherapy arrangement
US4946793A (en) 1986-05-09 1990-08-07 Electropore, Inc. Impedance matching for instrumentation which electrically alters vesicle membranes
US5019034A (en) 1988-01-21 1991-05-28 Massachusetts Institute Of Technology Control of transport of molecules across tissue using electroporation
DE4000893A1 (en) 1990-01-15 1991-07-18 Bosch Gmbh Robert Multichannel appts. for electro-simulation - provides several current circuits for patient with electrodes applying pulse signals
US5052391A (en) 1990-10-22 1991-10-01 R.F.P., Inc. High frequency high intensity transcutaneous electrical nerve stimulator and method of treatment
US5058605A (en) 1989-02-22 1991-10-22 Ceske Vysoke Uceni Technicke Method and device for the controlled local, non-invasive application of dc pulses to human and animal tissues
US5098843A (en) 1987-06-04 1992-03-24 Calvin Noel M Apparatus for the high efficiency transformation of living cells
US5134070A (en) 1990-06-04 1992-07-28 Casnig Dael R Method and device for cell cultivation on electrodes
US5173158A (en) 1991-07-22 1992-12-22 Schmukler Robert E Apparatus and methods for electroporation and electrofusion
US5193537A (en) 1990-06-12 1993-03-16 Zmd Corporation Method and apparatus for transcutaneous electrical cardiac pacing
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US5318563A (en) 1992-06-04 1994-06-07 Valley Forge Scientific Corporation Bipolar RF generator
US5328451A (en) 1991-08-15 1994-07-12 Board Of Regents, The University Of Texas System Iontophoretic device and method for killing bacteria and other microbes
US5389069A (en) 1988-01-21 1995-02-14 Massachusetts Institute Of Technology Method and apparatus for in vivo electroporation of remote cells and tissue
US5403311A (en) 1993-03-29 1995-04-04 Boston Scientific Corporation Electro-coagulation and ablation and other electrotherapeutic treatments of body tissue
US5425752A (en) 1991-11-25 1995-06-20 Vu'nguyen; Dung D. Method of direct electrical myostimulation using acupuncture needles
US5439440A (en) 1993-04-01 1995-08-08 Genetronics, Inc. Electroporation system with voltage control feedback for clinical applications
US5458625A (en) 1994-05-04 1995-10-17 Kendall; Donald E. Transcutaneous nerve stimulation device and method for using same
US5533999A (en) 1993-08-23 1996-07-09 Refractec, Inc. Method and apparatus for modifications of visual acuity by thermal means
US5536240A (en) 1992-08-12 1996-07-16 Vidamed, Inc. Medical probe device and method
US5575811A (en) 1993-07-08 1996-11-19 Urologix, Inc. Benign prostatic hyperplasia treatment catheter with urethral cooling
EP0378132B1 (en) 1989-01-09 1996-11-27 Cit Ionofor, S.L. A device for the administration of medication by iontopheresis for local - regional treatment.
US5626146A (en) 1992-12-18 1997-05-06 British Technology Group Limited Electrical impedance tomography
US5634899A (en) 1993-08-20 1997-06-03 Cortrak Medical, Inc. Simultaneous cardiac pacing and local drug delivery method
US5674267A (en) 1993-03-30 1997-10-07 Centre National De La Recherche Scientifique Electric pulse applicator using pairs of needle electrodes for the treatment of biological tissue
US5702359A (en) 1995-06-06 1997-12-30 Genetronics, Inc. Needle electrodes for mediated delivery of drugs and genes
US5720921A (en) 1995-03-10 1998-02-24 Entremed, Inc. Flow electroporation chamber and method
US5778894A (en) 1996-04-18 1998-07-14 Elizabeth Arden Co. Method for reducing human body cellulite by treatment with pulsed electromagnetic energy
US5782882A (en) 1995-11-30 1998-07-21 Hewlett-Packard Company System and method for administering transcutaneous cardiac pacing with transcutaneous electrical nerve stimulation
US5810762A (en) 1995-04-10 1998-09-22 Genetronics, Inc. Electroporation system with voltage control feedback for clinical applications
US5836905A (en) 1994-06-20 1998-11-17 Lemelson; Jerome H. Apparatus and methods for gene therapy
US5843026A (en) 1992-08-12 1998-12-01 Vidamed, Inc. BPH ablation method and apparatus
US5873849A (en) 1997-04-24 1999-02-23 Ichor Medical Systems, Inc. Electrodes and electrode arrays for generating electroporation inducing electrical fields
US5919142A (en) 1995-06-22 1999-07-06 Btg International Limited Electrical impedance tomography method and apparatus
US5947889A (en) 1995-01-17 1999-09-07 Hehrlein; Christoph Balloon catheter used to prevent re-stenosis after angioplasty and process for producing a balloon catheter
US5983131A (en) 1995-08-11 1999-11-09 Massachusetts Institute Of Technology Apparatus and method for electroporation of tissue
US5991697A (en) 1996-12-31 1999-11-23 The Regents Of The University Of California Method and apparatus for optical Doppler tomographic imaging of fluid flow velocity in highly scattering media
US5999847A (en) 1997-10-21 1999-12-07 Elstrom; John A. Apparatus and method for delivery of surgical and therapeutic agents
US6009347A (en) 1998-01-27 1999-12-28 Genetronics, Inc. Electroporation apparatus with connective electrode template
US6010613A (en) 1995-12-08 2000-01-04 Cyto Pulse Sciences, Inc. Method of treating materials with pulsed electrical fields
US6016452A (en) 1996-03-19 2000-01-18 Kasevich; Raymond S. Dynamic heating method and radio frequency thermal treatment
US6041252A (en) * 1995-06-07 2000-03-21 Ichor Medical Systems Inc. Drug delivery system and method
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US6085115A (en) 1997-05-22 2000-07-04 Massachusetts Institite Of Technology Biopotential measurement including electroporation of tissue surface
US6090106A (en) 1996-01-09 2000-07-18 Gyrus Medical Limited Electrosurgical instrument
US6102885A (en) 1996-08-08 2000-08-15 Bass; Lawrence S. Device for suction-assisted lipectomy and method of using same
US6106521A (en) 1996-08-16 2000-08-22 United States Surgical Corporation Apparatus for thermal treatment of tissue
US6109270A (en) 1997-02-04 2000-08-29 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Multimodality instrument for tissue characterization
US6122599A (en) 1998-02-13 2000-09-19 Mehta; Shailesh Apparatus and method for analyzing particles
US6132419A (en) 1992-05-22 2000-10-17 Genetronics, Inc. Electroporetic gene and drug therapy
US6159163A (en) 1998-05-07 2000-12-12 Cedars-Sinai Medical Center System for attenuating pain during bone marrow aspiration and method
US6208893B1 (en) 1998-01-27 2001-03-27 Genetronics, Inc. Electroporation apparatus with connective electrode template
US6212433B1 (en) 1998-07-28 2001-04-03 Radiotherapeutics Corporation Method for treating tumors near the surface of an organ
US6210402B1 (en) 1995-11-22 2001-04-03 Arthrocare Corporation Methods for electrosurgical dermatological treatment
US6216034B1 (en) 1997-08-01 2001-04-10 Genetronics, Inc. Method of programming an array of needle electrodes for electroporation therapy of tissue
US6219577B1 (en) 1998-04-14 2001-04-17 Global Vascular Concepts, Inc. Iontophoresis, electroporation and combination catheters for local drug delivery to arteries and other body tissues
US6241702B1 (en) 1992-08-12 2001-06-05 Vidamed, Inc. Radio frequency ablation device for treatment of the prostate
US6261831B1 (en) 1999-03-26 2001-07-17 The United States Of America As Represented By The Secretary Of The Air Force Ultra-wide band RF-enhanced chemotherapy for cancer treatmeat
US6300108B1 (en) 1999-07-21 2001-10-09 The Regents Of The University Of California Controlled electroporation and mass transfer across cell membranes
US20010044596A1 (en) 2000-05-10 2001-11-22 Ali Jaafar Apparatus and method for treatment of vascular restenosis by electroporation
US6326177B1 (en) 1999-08-04 2001-12-04 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Method and apparatus for intracellular electro-manipulation
US20020010491A1 (en) 1999-08-04 2002-01-24 Schoenbach Karl H. Method and apparatus for intracellular electro-manipulation
US6347247B1 (en) 1998-05-08 2002-02-12 Genetronics Inc. Electrically induced vessel vasodilation
US6349233B1 (en) 1993-02-22 2002-02-19 Angeion Corporation Neuro-stimulation to control pain during cardioversion defibrillation
US6351674B2 (en) 1998-11-23 2002-02-26 Synaptic Corporation Method for inducing electroanesthesia using high frequency, high intensity transcutaneous electrical nerve stimulation
US20020055731A1 (en) 1997-10-24 2002-05-09 Anthony Atala Methods for promoting cell transfection in vivo
US6387671B1 (en) 1999-07-21 2002-05-14 The Regents Of The University Of California Electrical impedance tomography to control electroporation
US6403348B1 (en) 1999-07-21 2002-06-11 The Regents Of The University Of California Controlled electroporation and mass transfer across cell membranes
US20020077676A1 (en) 1999-04-09 2002-06-20 Schroeppel Edward A. Implantable device and method for the electrical treatment of cancer
US20020099323A1 (en) 1998-07-13 2002-07-25 Nagendu B. Dev Skin and muscle-targeted gene therapy by pulsed electrical field
US20020138117A1 (en) 2000-06-21 2002-09-26 Son Young Tae Apparatus and method for selectively removing a body fat mass in human body
US6470211B1 (en) 1997-06-03 2002-10-22 Uab Research Foundation Method and apparatus for treating cardiac arrhythmia
US6493592B1 (en) 1999-12-01 2002-12-10 Vertis Neuroscience, Inc. Percutaneous electrical therapy system with electrode position maintenance
US20020193831A1 (en) 2001-04-26 2002-12-19 Smith Edward Dewey Method and apparatus for the treatment of cosmetic skin conditions
US6500173B2 (en) 1992-01-07 2002-12-31 Ronald A. Underwood Methods for electrosurgical spine surgery
US20030009110A1 (en) 2001-07-06 2003-01-09 Hosheng Tu Device for tumor diagnosis and methods thereof
US6526320B2 (en) 1998-11-16 2003-02-25 United States Surgical Corporation Apparatus for thermal treatment of tissue
US20030060856A1 (en) 2001-08-13 2003-03-27 Victor Chornenky Apparatus and method for treatment of benign prostatic hyperplasia
US20030088189A1 (en) 2001-11-05 2003-05-08 Hosheng Tu Apparatus and methods for monitoring tissue impedance
US20030130711A1 (en) 2001-09-28 2003-07-10 Pearson Robert M. Impedance controlled tissue ablation apparatus and method
US6607529B1 (en) 1995-06-19 2003-08-19 Medtronic Vidamed, Inc. Electrosurgical device
US6611706B2 (en) 1998-11-09 2003-08-26 Transpharma Ltd. Monopolar and bipolar current application for transdermal drug delivery and analyte extraction
US6613211B1 (en) 1999-08-27 2003-09-02 Aclara Biosciences, Inc. Capillary electrokinesis based cellular assays
US20030170898A1 (en) 2001-12-04 2003-09-11 Gundersen Martin A. Method for intracellular modifications within living cells using pulsed electric fields
US6627421B1 (en) 1999-04-13 2003-09-30 Imarx Therapeutics, Inc. Methods and systems for applying multi-mode energy to biological samples
US20030208200A1 (en) 2002-05-03 2003-11-06 Palanker Daniel V. Method and apparatus for plasma-mediated thermo-electrical ablation
US6653091B1 (en) 1998-09-30 2003-11-25 Cyngnus, Inc. Method and device for predicting physiological values
US20030225360A1 (en) 2002-03-11 2003-12-04 Jonathan Eppstein Transdermal drug delivery patch system, method of making same and method of using same
US6669691B1 (en) 2000-07-18 2003-12-30 Scimed Life Systems, Inc. Epicardial myocardial revascularization and denervation methods and apparatus
US6678558B1 (en) * 1999-03-25 2004-01-13 Genetronics, Inc. Method and apparatus for reducing electroporation-mediated muscle reaction and pain response
US20040019371A1 (en) 2001-02-08 2004-01-29 Ali Jaafar Apparatus and method for reducing subcutaneous fat deposits, virtual face lift and body sculpturing by electroporation
US6692493B2 (en) 1998-02-11 2004-02-17 Cosman Company, Inc. Method for performing intraurethral radio-frequency urethral enlargement
US6697670B2 (en) 2001-08-17 2004-02-24 Minnesota Medical Physics, Llc Apparatus and method for reducing subcutaneous fat deposits by electroporation with improved comfort of patients
US6702808B1 (en) 2000-09-28 2004-03-09 Syneron Medical Ltd. Device and method for treating skin
US20040059389A1 (en) 2002-08-13 2004-03-25 Chornenky Victor I. Apparatus and method for the treatment of benign prostatic hyperplasia
US20040146877A1 (en) 2001-04-12 2004-07-29 Diss James K.J. Diagnosis and treatment of cancer:I
US20040153057A1 (en) 1998-11-20 2004-08-05 Arthrocare Corporation Electrosurgical apparatus and methods for ablating tissue
US6795728B2 (en) 2001-08-17 2004-09-21 Minnesota Medical Physics, Llc Apparatus and method for reducing subcutaneous fat deposits by electroporation
US6801804B2 (en) 2002-05-03 2004-10-05 Aciont, Inc. Device and method for monitoring and controlling electrical resistance at a tissue site undergoing iontophoresis
US20040243107A1 (en) 2001-10-01 2004-12-02 Macoviak John A Methods and devices for treating atrial fibrilation
US20040267189A1 (en) 2001-10-24 2004-12-30 Daniela Mavor Device and method for controlled delivery of active substance into the skin
US20050043726A1 (en) 2001-03-07 2005-02-24 Mchale Anthony Patrick Device II
US20050049541A1 (en) 2001-10-12 2005-03-03 Francine Behar Device for medicine delivery by intraocular iontophoresis or electroporation
EP0935482B1 (en) 1996-07-18 2005-05-04 Radinvent AB An apparatus for treating tumoral diseases (cancer)
US6912417B1 (en) 2002-04-05 2005-06-28 Ichor Medical Systmes, Inc. Method and apparatus for delivery of therapeutic agents
US20050165393A1 (en) 1996-12-31 2005-07-28 Eppstein Jonathan A. Microporation of tissue for delivery of bioactive agents
US20050171574A1 (en) 2003-12-24 2005-08-04 The Regents Of The University Of California Electroporation to interrupt blood flow
US6927049B2 (en) 1999-07-21 2005-08-09 The Regents Of The University Of California Cell viability detection using electrical measurements
US6962587B2 (en) 2000-07-25 2005-11-08 Rita Medical Systems, Inc. Method for detecting and treating tumors using localized impedance measurement
US20050261672A1 (en) 2004-05-18 2005-11-24 Mark Deem Systems and methods for selective denervation of heart dysrhythmias
US6972014B2 (en) 2003-01-04 2005-12-06 Endocare, Inc. Open system heat exchange catheters and methods of use
US20050288730A1 (en) 2002-04-08 2005-12-29 Mark Deem Methods and apparatus for renal neuromodulation
US20060015147A1 (en) 1998-03-31 2006-01-19 Aditus Medical Ab. Apparatus for controlling the generation of electric fields
US20060025760A1 (en) 2002-05-06 2006-02-02 Podhajsky Ronald J Blood detector for controlling anesu and method therefor
US20060079883A1 (en) 2004-10-13 2006-04-13 Ahmed Elmouelhi Transurethral needle ablation system
US7053063B2 (en) 1999-07-21 2006-05-30 The Regents Of The University Of California Controlled electroporation and mass transfer across cell membranes in tissue
US7063698B2 (en) 2002-06-14 2006-06-20 Ncontact Surgical, Inc. Vacuum coagulation probes
US20060212078A1 (en) 2002-04-08 2006-09-21 Ardian, Inc. Methods and apparatus for treating congestive heart failure
US20060264752A1 (en) 2005-04-27 2006-11-23 The Regents Of The University Of California Electroporation controlled with real time imaging
US7211083B2 (en) 2003-03-17 2007-05-01 Minnesota Medical Physics, Llc Apparatus and method for hair removal by electroporation
US20080052786A1 (en) 2006-08-24 2008-02-28 Pei-Cheng Lin Animal Model of Prostate Cancer and Use Thereof

Patent Citations (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1653819A (en) 1926-08-07 1927-12-27 Northcott Ephraim Electrotherapeutical apparatus
DE863111C (en) 1951-07-03 1953-01-15 Walter Hallegger Instrument for transcutaneous and subcutaneous heating and iontophoresis and method of its use
US4016886A (en) 1974-11-26 1977-04-12 The United States Of America As Represented By The United States Energy Research And Development Administration Method for localizing heating in tumor tissue
US4407943A (en) 1976-12-16 1983-10-04 Millipore Corporation Immobilized antibody or antigen for immunoassay
US4226246A (en) 1977-05-27 1980-10-07 Carba Societe Anonyme Apparatus for maintaining the negative potential of human, animal, and plant cells
US4262672A (en) 1978-01-02 1981-04-21 Horst Kief Acupuncture instrument
US4810963A (en) 1984-04-03 1989-03-07 Public Health Laboratory Service Board Method for investigating the condition of a bacterial suspension through frequency profile of electrical admittance
US4946793A (en) 1986-05-09 1990-08-07 Electropore, Inc. Impedance matching for instrumentation which electrically alters vesicle membranes
US5098843A (en) 1987-06-04 1992-03-24 Calvin Noel M Apparatus for the high efficiency transformation of living cells
US5019034A (en) 1988-01-21 1991-05-28 Massachusetts Institute Of Technology Control of transport of molecules across tissue using electroporation
US5019034B1 (en) 1988-01-21 1995-08-15 Massachusetts Inst Technology Control of transport of molecules across tissue using electroporation
US5389069A (en) 1988-01-21 1995-02-14 Massachusetts Institute Of Technology Method and apparatus for in vivo electroporation of remote cells and tissue
US4907601A (en) 1988-06-15 1990-03-13 Etama Ag Electrotherapy arrangement
EP0378132B1 (en) 1989-01-09 1996-11-27 Cit Ionofor, S.L. A device for the administration of medication by iontopheresis for local - regional treatment.
US5058605A (en) 1989-02-22 1991-10-22 Ceske Vysoke Uceni Technicke Method and device for the controlled local, non-invasive application of dc pulses to human and animal tissues
DE4000893A1 (en) 1990-01-15 1991-07-18 Bosch Gmbh Robert Multichannel appts. for electro-simulation - provides several current circuits for patient with electrodes applying pulse signals
US5134070A (en) 1990-06-04 1992-07-28 Casnig Dael R Method and device for cell cultivation on electrodes
US5193537A (en) 1990-06-12 1993-03-16 Zmd Corporation Method and apparatus for transcutaneous electrical cardiac pacing
US5052391A (en) 1990-10-22 1991-10-01 R.F.P., Inc. High frequency high intensity transcutaneous electrical nerve stimulator and method of treatment
US5173158A (en) 1991-07-22 1992-12-22 Schmukler Robert E Apparatus and methods for electroporation and electrofusion
US5283194A (en) 1991-07-22 1994-02-01 Schmukler Robert E Apparatus and methods for electroporation and electrofusion
US5328451A (en) 1991-08-15 1994-07-12 Board Of Regents, The University Of Texas System Iontophoretic device and method for killing bacteria and other microbes
US5425752A (en) 1991-11-25 1995-06-20 Vu'nguyen; Dung D. Method of direct electrical myostimulation using acupuncture needles
US6500173B2 (en) 1992-01-07 2002-12-31 Ronald A. Underwood Methods for electrosurgical spine surgery
US6132419A (en) 1992-05-22 2000-10-17 Genetronics, Inc. Electroporetic gene and drug therapy
US5318563A (en) 1992-06-04 1994-06-07 Valley Forge Scientific Corporation Bipolar RF generator
US5843026A (en) 1992-08-12 1998-12-01 Vidamed, Inc. BPH ablation method and apparatus
US5800378A (en) 1992-08-12 1998-09-01 Vidamed, Inc. Medical probe device and method
US6241702B1 (en) 1992-08-12 2001-06-05 Vidamed, Inc. Radio frequency ablation device for treatment of the prostate
US5536240A (en) 1992-08-12 1996-07-16 Vidamed, Inc. Medical probe device and method
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US5626146A (en) 1992-12-18 1997-05-06 British Technology Group Limited Electrical impedance tomography
US6349233B1 (en) 1993-02-22 2002-02-19 Angeion Corporation Neuro-stimulation to control pain during cardioversion defibrillation
US5403311A (en) 1993-03-29 1995-04-04 Boston Scientific Corporation Electro-coagulation and ablation and other electrotherapeutic treatments of body tissue
US5674267A (en) 1993-03-30 1997-10-07 Centre National De La Recherche Scientifique Electric pulse applicator using pairs of needle electrodes for the treatment of biological tissue
US5439440A (en) 1993-04-01 1995-08-08 Genetronics, Inc. Electroporation system with voltage control feedback for clinical applications
US5575811A (en) 1993-07-08 1996-11-19 Urologix, Inc. Benign prostatic hyperplasia treatment catheter with urethral cooling
US5634899A (en) 1993-08-20 1997-06-03 Cortrak Medical, Inc. Simultaneous cardiac pacing and local drug delivery method
US5533999A (en) 1993-08-23 1996-07-09 Refractec, Inc. Method and apparatus for modifications of visual acuity by thermal means
US5458625A (en) 1994-05-04 1995-10-17 Kendall; Donald E. Transcutaneous nerve stimulation device and method for using same
US5836905A (en) 1994-06-20 1998-11-17 Lemelson; Jerome H. Apparatus and methods for gene therapy
US5947889A (en) 1995-01-17 1999-09-07 Hehrlein; Christoph Balloon catheter used to prevent re-stenosis after angioplasty and process for producing a balloon catheter
US5720921A (en) 1995-03-10 1998-02-24 Entremed, Inc. Flow electroporation chamber and method
US5810762A (en) 1995-04-10 1998-09-22 Genetronics, Inc. Electroporation system with voltage control feedback for clinical applications
US5702359A (en) 1995-06-06 1997-12-30 Genetronics, Inc. Needle electrodes for mediated delivery of drugs and genes
US6041252A (en) * 1995-06-07 2000-03-21 Ichor Medical Systems Inc. Drug delivery system and method
US6607529B1 (en) 1995-06-19 2003-08-19 Medtronic Vidamed, Inc. Electrosurgical device
US5919142A (en) 1995-06-22 1999-07-06 Btg International Limited Electrical impedance tomography method and apparatus
US5983131A (en) 1995-08-11 1999-11-09 Massachusetts Institute Of Technology Apparatus and method for electroporation of tissue
US6210402B1 (en) 1995-11-22 2001-04-03 Arthrocare Corporation Methods for electrosurgical dermatological treatment
US5782882A (en) 1995-11-30 1998-07-21 Hewlett-Packard Company System and method for administering transcutaneous cardiac pacing with transcutaneous electrical nerve stimulation
US6010613A (en) 1995-12-08 2000-01-04 Cyto Pulse Sciences, Inc. Method of treating materials with pulsed electrical fields
US6090106A (en) 1996-01-09 2000-07-18 Gyrus Medical Limited Electrosurgical instrument
US6016452A (en) 1996-03-19 2000-01-18 Kasevich; Raymond S. Dynamic heating method and radio frequency thermal treatment
US5778894A (en) 1996-04-18 1998-07-14 Elizabeth Arden Co. Method for reducing human body cellulite by treatment with pulsed electromagnetic energy
EP0935482B1 (en) 1996-07-18 2005-05-04 Radinvent AB An apparatus for treating tumoral diseases (cancer)
US6102885A (en) 1996-08-08 2000-08-15 Bass; Lawrence S. Device for suction-assisted lipectomy and method of using same
US6106521A (en) 1996-08-16 2000-08-22 United States Surgical Corporation Apparatus for thermal treatment of tissue
US20050165393A1 (en) 1996-12-31 2005-07-28 Eppstein Jonathan A. Microporation of tissue for delivery of bioactive agents
US5991697A (en) 1996-12-31 1999-11-23 The Regents Of The University Of California Method and apparatus for optical Doppler tomographic imaging of fluid flow velocity in highly scattering media
US6109270A (en) 1997-02-04 2000-08-29 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Multimodality instrument for tissue characterization
US6278895B1 (en) 1997-04-24 2001-08-21 Ichor Medical Systems, Inc. Electrodes and electrode arrays for generating electroporation inducing electrical fields
US5873849A (en) 1997-04-24 1999-02-23 Ichor Medical Systems, Inc. Electrodes and electrode arrays for generating electroporation inducing electrical fields
US6085115A (en) 1997-05-22 2000-07-04 Massachusetts Institite Of Technology Biopotential measurement including electroporation of tissue surface
US6470211B1 (en) 1997-06-03 2002-10-22 Uab Research Foundation Method and apparatus for treating cardiac arrhythmia
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US6216034B1 (en) 1997-08-01 2001-04-10 Genetronics, Inc. Method of programming an array of needle electrodes for electroporation therapy of tissue
US6068650A (en) 1997-08-01 2000-05-30 Gentronics Inc. Method of Selectively applying needle array configurations
US5999847A (en) 1997-10-21 1999-12-07 Elstrom; John A. Apparatus and method for delivery of surgical and therapeutic agents
US20020055731A1 (en) 1997-10-24 2002-05-09 Anthony Atala Methods for promoting cell transfection in vivo
US6208893B1 (en) 1998-01-27 2001-03-27 Genetronics, Inc. Electroporation apparatus with connective electrode template
US6009347A (en) 1998-01-27 1999-12-28 Genetronics, Inc. Electroporation apparatus with connective electrode template
US6692493B2 (en) 1998-02-11 2004-02-17 Cosman Company, Inc. Method for performing intraurethral radio-frequency urethral enlargement
US6122599A (en) 1998-02-13 2000-09-19 Mehta; Shailesh Apparatus and method for analyzing particles
US20070118069A1 (en) 1998-03-31 2007-05-24 Aditus Medical Ab Apparatus for controlling the generation of electric fields
US20060015147A1 (en) 1998-03-31 2006-01-19 Aditus Medical Ab. Apparatus for controlling the generation of electric fields
US6219577B1 (en) 1998-04-14 2001-04-17 Global Vascular Concepts, Inc. Iontophoresis, electroporation and combination catheters for local drug delivery to arteries and other body tissues
US6159163A (en) 1998-05-07 2000-12-12 Cedars-Sinai Medical Center System for attenuating pain during bone marrow aspiration and method
US6347247B1 (en) 1998-05-08 2002-02-12 Genetronics Inc. Electrically induced vessel vasodilation
US6865416B2 (en) 1998-05-08 2005-03-08 Genetronics, Inc. Electrically induced vessel vasodilation
US6697669B2 (en) 1998-07-13 2004-02-24 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US20020099323A1 (en) 1998-07-13 2002-07-25 Nagendu B. Dev Skin and muscle-targeted gene therapy by pulsed electrical field
US6212433B1 (en) 1998-07-28 2001-04-03 Radiotherapeutics Corporation Method for treating tumors near the surface of an organ
US6653091B1 (en) 1998-09-30 2003-11-25 Cyngnus, Inc. Method and device for predicting physiological values
US6611706B2 (en) 1998-11-09 2003-08-26 Transpharma Ltd. Monopolar and bipolar current application for transdermal drug delivery and analyte extraction
US6526320B2 (en) 1998-11-16 2003-02-25 United States Surgical Corporation Apparatus for thermal treatment of tissue
US20040153057A1 (en) 1998-11-20 2004-08-05 Arthrocare Corporation Electrosurgical apparatus and methods for ablating tissue
US6351674B2 (en) 1998-11-23 2002-02-26 Synaptic Corporation Method for inducing electroanesthesia using high frequency, high intensity transcutaneous electrical nerve stimulation
US6678558B1 (en) * 1999-03-25 2004-01-13 Genetronics, Inc. Method and apparatus for reducing electroporation-mediated muscle reaction and pain response
US6261831B1 (en) 1999-03-26 2001-07-17 The United States Of America As Represented By The Secretary Of The Air Force Ultra-wide band RF-enhanced chemotherapy for cancer treatmeat
US20020077676A1 (en) 1999-04-09 2002-06-20 Schroeppel Edward A. Implantable device and method for the electrical treatment of cancer
US6627421B1 (en) 1999-04-13 2003-09-30 Imarx Therapeutics, Inc. Methods and systems for applying multi-mode energy to biological samples
US6562604B2 (en) 1999-07-21 2003-05-13 The Regents Of The University Of California Controlled electroporation and mass transfer across cell membranes
US6482619B1 (en) 1999-07-21 2002-11-19 The Regents Of The University Of California Cell/tissue analysis via controlled electroporation
US20060121610A1 (en) 1999-07-21 2006-06-08 The Regents Of The University Of California Controlled electroporation and mass transfer across cell membranes
US6387671B1 (en) 1999-07-21 2002-05-14 The Regents Of The University Of California Electrical impedance tomography to control electroporation
US6300108B1 (en) 1999-07-21 2001-10-09 The Regents Of The University Of California Controlled electroporation and mass transfer across cell membranes
US6403348B1 (en) 1999-07-21 2002-06-11 The Regents Of The University Of California Controlled electroporation and mass transfer across cell membranes
US6927049B2 (en) 1999-07-21 2005-08-09 The Regents Of The University Of California Cell viability detection using electrical measurements
US7053063B2 (en) 1999-07-21 2006-05-30 The Regents Of The University Of California Controlled electroporation and mass transfer across cell membranes in tissue
US20020010491A1 (en) 1999-08-04 2002-01-24 Schoenbach Karl H. Method and apparatus for intracellular electro-manipulation
US6326177B1 (en) 1999-08-04 2001-12-04 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Method and apparatus for intracellular electro-manipulation
US6613211B1 (en) 1999-08-27 2003-09-02 Aclara Biosciences, Inc. Capillary electrokinesis based cellular assays
US6493592B1 (en) 1999-12-01 2002-12-10 Vertis Neuroscience, Inc. Percutaneous electrical therapy system with electrode position maintenance
US20010044596A1 (en) 2000-05-10 2001-11-22 Ali Jaafar Apparatus and method for treatment of vascular restenosis by electroporation
US20020138117A1 (en) 2000-06-21 2002-09-26 Son Young Tae Apparatus and method for selectively removing a body fat mass in human body
US6669691B1 (en) 2000-07-18 2003-12-30 Scimed Life Systems, Inc. Epicardial myocardial revascularization and denervation methods and apparatus
US6962587B2 (en) 2000-07-25 2005-11-08 Rita Medical Systems, Inc. Method for detecting and treating tumors using localized impedance measurement
US20050182462A1 (en) 2000-08-17 2005-08-18 Chornenky Victor I. Apparatus and method for reducing subcutaneous fat deposits, virtual face lift and body sculpturing by electroporation
US6702808B1 (en) 2000-09-28 2004-03-09 Syneron Medical Ltd. Device and method for treating skin
US20040019371A1 (en) 2001-02-08 2004-01-29 Ali Jaafar Apparatus and method for reducing subcutaneous fat deposits, virtual face lift and body sculpturing by electroporation
US6892099B2 (en) 2001-02-08 2005-05-10 Minnesota Medical Physics, Llc Apparatus and method for reducing subcutaneous fat deposits, virtual face lift and body sculpturing by electroporation
US20050043726A1 (en) 2001-03-07 2005-02-24 Mchale Anthony Patrick Device II
US20040146877A1 (en) 2001-04-12 2004-07-29 Diss James K.J. Diagnosis and treatment of cancer:I
US20020193831A1 (en) 2001-04-26 2002-12-19 Smith Edward Dewey Method and apparatus for the treatment of cosmetic skin conditions
US20030009110A1 (en) 2001-07-06 2003-01-09 Hosheng Tu Device for tumor diagnosis and methods thereof
US20060217703A1 (en) 2001-08-13 2006-09-28 Chornenky Victor I Apparatus and method for treatment of benign prostatic hyperplasia
US6994706B2 (en) 2001-08-13 2006-02-07 Minnesota Medical Physics, Llc Apparatus and method for treatment of benign prostatic hyperplasia
US20030060856A1 (en) 2001-08-13 2003-03-27 Victor Chornenky Apparatus and method for treatment of benign prostatic hyperplasia
US6697670B2 (en) 2001-08-17 2004-02-24 Minnesota Medical Physics, Llc Apparatus and method for reducing subcutaneous fat deposits by electroporation with improved comfort of patients
US6795728B2 (en) 2001-08-17 2004-09-21 Minnesota Medical Physics, Llc Apparatus and method for reducing subcutaneous fat deposits by electroporation
US20030130711A1 (en) 2001-09-28 2003-07-10 Pearson Robert M. Impedance controlled tissue ablation apparatus and method
US20040243107A1 (en) 2001-10-01 2004-12-02 Macoviak John A Methods and devices for treating atrial fibrilation
US20050049541A1 (en) 2001-10-12 2005-03-03 Francine Behar Device for medicine delivery by intraocular iontophoresis or electroporation
US20040267189A1 (en) 2001-10-24 2004-12-30 Daniela Mavor Device and method for controlled delivery of active substance into the skin
US20030088189A1 (en) 2001-11-05 2003-05-08 Hosheng Tu Apparatus and methods for monitoring tissue impedance
US20030170898A1 (en) 2001-12-04 2003-09-11 Gundersen Martin A. Method for intracellular modifications within living cells using pulsed electric fields
US20030225360A1 (en) 2002-03-11 2003-12-04 Jonathan Eppstein Transdermal drug delivery patch system, method of making same and method of using same
US6912417B1 (en) 2002-04-05 2005-06-28 Ichor Medical Systmes, Inc. Method and apparatus for delivery of therapeutic agents
US20050288730A1 (en) 2002-04-08 2005-12-29 Mark Deem Methods and apparatus for renal neuromodulation
US20060212078A1 (en) 2002-04-08 2006-09-21 Ardian, Inc. Methods and apparatus for treating congestive heart failure
US6801804B2 (en) 2002-05-03 2004-10-05 Aciont, Inc. Device and method for monitoring and controlling electrical resistance at a tissue site undergoing iontophoresis
US20030208200A1 (en) 2002-05-03 2003-11-06 Palanker Daniel V. Method and apparatus for plasma-mediated thermo-electrical ablation
US20060025760A1 (en) 2002-05-06 2006-02-02 Podhajsky Ronald J Blood detector for controlling anesu and method therefor
US7063698B2 (en) 2002-06-14 2006-06-20 Ncontact Surgical, Inc. Vacuum coagulation probes
US20040059389A1 (en) 2002-08-13 2004-03-25 Chornenky Victor I. Apparatus and method for the treatment of benign prostatic hyperplasia
US7130697B2 (en) 2002-08-13 2006-10-31 Minnesota Medical Physics Llc Apparatus and method for the treatment of benign prostatic hyperplasia
US6972014B2 (en) 2003-01-04 2005-12-06 Endocare, Inc. Open system heat exchange catheters and methods of use
US7211083B2 (en) 2003-03-17 2007-05-01 Minnesota Medical Physics, Llc Apparatus and method for hair removal by electroporation
US7267676B2 (en) 2003-03-17 2007-09-11 Minnesota Medical Physics Llc Method for hair removal by electroporation
US20050171574A1 (en) 2003-12-24 2005-08-04 The Regents Of The University Of California Electroporation to interrupt blood flow
US20070043345A1 (en) 2003-12-24 2007-02-22 Rafael Davalos Tissue ablation with irreversible electroporation
US20050171523A1 (en) 2003-12-24 2005-08-04 The Regents Of The University Of California Irreversible electroporation to control bleeding
US20050261672A1 (en) 2004-05-18 2005-11-24 Mark Deem Systems and methods for selective denervation of heart dysrhythmias
US20060079883A1 (en) 2004-10-13 2006-04-13 Ahmed Elmouelhi Transurethral needle ablation system
US20060264752A1 (en) 2005-04-27 2006-11-23 The Regents Of The University Of California Electroporation controlled with real time imaging
US20080052786A1 (en) 2006-08-24 2008-02-28 Pei-Cheng Lin Animal Model of Prostate Cancer and Use Thereof

Non-Patent Citations (89)

* Cited by examiner, † Cited by third party
Title
Amasha, et al., Quantitative Assessment of Impedance Tomography for Temperature Measurements in Microwave Hyperthermia, Clin. Phys. Physiol. Meas., 1998, Suppl. A, 49-53.
Andreason, Electroporation as a Technique for the Transfer of Macromolecules into Mammalian Cell Lines, J. Tiss. Cult. Meth., 15:56-62, 1993.
Baker, et al., Calcium-Dependent Exocytosis in Bovine Adrenal Medullary Cells with Leaky Plasma Membranes, Nature, vol. 276, pp. 620-622, 1978.
Barber, Electrical Impedance Tomography Applied Potential Tomography, Advances in Biomedical Engineering, Beneken and Thevenin, eds., IOS Press, 1993.
Beebe, S.J., et al., Nanosecond pulsed electric field (nsPEF) effects on cells and tissues: apoptosis induction and tumor growth inhibition. PPPS-2001 Pulsed Power Plasma Science 2001, 28th IEEE International Conference on Plasma Science and 13th IEEE International Pulsed Power Conference, Digest of Technical Papers (Cat. No. 01CH37251). IEEE, Part vol. 1, 2001, pp. 211-215, vol. I, Piscataway, NJ, USA.
Blad, et al., Impedance Spectra of Tumour Tissue in Comparison with Normal Tissue; a Possible Clinical Application for Electrical Impedance Tomography, Physiol. Meas. 17 (1996) A105-A115.
Bown, S.G., Phototherapy of tumors. World J. Surgery, 1983. 7: p. 700-9.
BPH Management Strategies: Improving Patient Satisfaction, Urology Times, May 2001, vol. 29, Supplement 1.
Brown, et al., Blood Flow Imaging Using Electrical Impedance Tomography, Clin. Phys. Physiol. Meas., 1992, vol. 13, Suppl. A, 175-179.
Chandrasekar, et al., Transurethral Needle Ablation of the Prostate (TUNA)-a Propsective Study, Six Year Follow Up, (Abstract), Presented at 2001 National Meeting, Anaheim, CA, Jun. 5, 2001.
Coates, C.W.,et al., "The Electrical Discharge of the Electric Eel, Electrophorous Electricus," Zoologica, 1937, 22(1), pp. 1-32.
Cook, et al., ACT3: A High-Speed, High-Precision Electrical Impedance Tomograph, IEEE Transactions on Biomedical Engineering, vol. 41, No. 8, Aug. 1994.
Cowley, Good News for Boomers, Newsweek, Dec. 30, 1996/Jan. 6, 1997.
Cox, et al., Surgical Treatment of Atrial Fibrillation: A Review, Europace (2004) 5, S20-S-29.
Crowley, Electrical Breakdown of Biomolecular Lipid Membranes as an Electromechanical Instability, Biophysical Journal, vol. 13, pp. 711-724, 1973.
Davalos, et al ., Theoretical Analysis of the Thermal Effects During In Vivo Tissue Electroporation, Bioelectrochemistry, vol. 61, pp. 99-107, 2003.
Davalos, et al., A Feasibility Study for Electrical Impedance Tomography as a Means to Monitor T issue Electroporation for Molecular Medicine, IEEE Transactions on Biomedical Engineering, vol. 49, No. 4, Apr. 2002.
Davalos, et al., Tissue Ablation with Irreversible Electroporation, Annals of Biomedical Engineering, vol. 33, No. 2, Feb. 2005.
Davalos, Real-Time Imaging for Molecular Medicine through Electrical Impedance Tomography of Electroporation, Dissertation for Ph.D. in Engineering-Mechanical Engineering, Graduate Division of University of California, Berkeley, 2002.
Dean, Nonviral Gene Transfer to Skeletal, Smooth, and Cardiac Muscle in Living Animals, Am J. Physiol Cell Physiol 289: 233-245, 2005.
Dev, et al., Medical Applications of Electroporation, IEEE Transactions of Plasma Science, vol. 28, No. 1, pp. 206-223, Feb. 2000.
Dev, et al., Sustained Local Delivery of Heparin to the Rabbit Arterial Wall with an Electroporation Catheter, Catheterization and Cardiovascular Diagnosis, Nov. 1998, vol. 45, No. 3, pp. 337-343.
Duraiswami, et al., Boundary Element Techniques for Efficient 2-D and 3-D Electrical Impedance Tomography, Chemical Engineering Science, vol. 52, No. 13, pp. 2185-2196, 1997.
Duraiswami, et al., Efficient 2D and 3D Electrical Impedance Tomography Using Dual Reciprocity Boundary Element Techniques, Engineering Analysis with Boundary Elements 22, (1998) 13-31.
Duraiswami, et al., Solution of Electrical Impedance Tomography Equations Using Boundary Element Methods, Boundary Element Technology XII, 1997, pp. 226-237.
Edd, J., et al., In-Vivo Results of a New Focal Tissue Ablation Technique: Irreversible Electroporaton, IEEE Trans. Biomed. Eng. 53 (2006) p. 1409-1415.
Erez, et al., Controlled Destruction and Temperature Distributions in Biological Tissues Subjected to Monoactive Electrocoagulation, Transactions of the ASME: Journal of Mechanical Design, vol. 102, Feb. 1980.
Foster, R.S., et al., High-intensity focused ultrasound in the treatment of prostatic disease. Eur. Urol., 1993. 23: 44-7).
Fox, et al., Sampling Conductivity Images via MCMC, Mathematics Department, Auckland University, New Zealand, May 1997.
Gauger, et al., A Study of Dielectric Membrane Breakdown in the Fucus Egg, J. Membrane Biol., vol. 48, No. 3, pp. 249-264, 1979.
Gehl, et al., In Vivo Electroporation of Skeletal Muscle: Threshold, Efficacy and Relation to Electric Field Distribution, Biochimica et Biphysica Acta 1428, 1999, pp. 233-240.
Gençer, et al., Electrical Impedance Tomography: Induced-Current Imaging Achieved with a Multiple Coil System, IEEE Transactions on Biomedical Engineering, vol. 43, No. 2, Feb. 1996.
Gilbert, et al., Novel Electrode Designs for Electrochemotherapy, Biochimica et Biophysica Acta 1334, 1997, pp. 9-14.
Gilbert, et al., The Use of Ultrasound Imaging for Monitoring Cryosurgery, Proceedings 6th Annual Conference, IEEE Engineering in Medicine and Biology, 107-111, 1984.
Glidewell, et al., The Use of Magnetic Resonance Imaging Data and the Inclusion of Anisotropic Regions in Electrical Impedance Tomography, Biomed, Sci. Instrum. 1993; 29: 251-7.
Gothelf, et al., Electrochemotherapy: Results of Cancer Treatment Using Enhanced Delivery of Bleomycin by Electroporation, Cancer Treatment Reviews 2003: 29: 371-387.
Griffiths, et al., A Dual-Frequency Electrical Impedance Tomography System, Phys. Med. Biol., 1989, vol. 34, No. 10, pp. 1465-1476.
Griffiths, The Importance of Phase Measurement in Electrical Impedance Tomography, Phys. Med. Biol., 1987, vol. 32, No. 11, pp. 1435-1444.
Griffiths, Tissue Spectroscopy with Electrical Impedance Tomography: Computer Simulations, IEEE Transactions on Biomedical Engineering, vol. 42, No. 9, Sep. 1995.
Gumerov, et al., The Dipole Approximation Method and Its Coupling with the Regular Boundary Element Method for Efficient Electrical Impedance Tomography, Boundary Element Technology XIII, 1999.
Hapala, Breaking the Barrier: Methods for Reversible Permeabilization of Cellular Membranes, Critical Reviews in Biotechnology, 17(2): 105-122, 1997.
Heller, et al., Clinical Applications of Electrochemotherapy, Advanced Drug Delivery Reviews, vol. 35, pp. 119-129, 1999.
Ho, et al., Electroporation of Cell Membranes: A Review, Critical Reviews in Biotechnology, 16(4): 349-362, 1996.
Holder, et al., Assessment and Calibration of a Low-Frequency System for Electrical Impedance Tomography (EIT), Optimized for Use in Imaging Brain Function in Ambulant Human Subjects, Annals of the New York Academy of Science, vol. 873, Issue 1, Electrical BI, pp. 512-519, 1999.
Huang, et al., Micro-Electroporation: Improving the Efficiency and Understanding of Electrical Permeabilization of Cells, Biomedical Microdevices, vol. 2, pp. 145-150, 1999.
Hughes, et al., An Analysis of Studies Comparing Electrical Impedance Tomography with X-Ray Videofluoroscopy in the Assessment of Swallowing, Physiol. Meas. 15, 1994, pp. A199-A209.
Issa, et al., The TUNA Procedure for BPH: Review of the Technology: The TUNA Procedure for BPH: Basic Procedure and Clinical Results, Reprinted from Infections in Urology, Jul./Aug. 1998 and Sep./Oct. 1998.
Ivanu{hacek over (s)}a, et al., MRI Macromolecular Contrast Agents as Indicators of Changed Tumor Blood Flow, Radiol. Oncol. 2001; 35(2): 139-47.
Jaroszeski, et al., In Vivo Gene Delivery by Electroporation, Advanced Drug Delivery Review, vol. 35, pp. 131-137, 1999.
Kinosita, et al., Hemolysis of Human Erythrocytes by a Transient Electric Field, Proc. Natl. Acad. Sci. USA, vol. 74, No. 5, pp. 1923-1927, 1977.
Liu, et al., Measurement of Pharyngeal Transit Time by Electrical Impedance Tomography, Clin. Phys. Physiol. Meas., 1992, vol. 13, Suppl. A, pp. 197-200.
Lundqvist, et al., Altering the Biochemical State of Individual Cultured Cells and Organelles with Ultramicroelectrodes, Proc. Natl. Acad. Sci. USA, vol. 95, pp. 10356-10360, Sep. 1998.
Lurquin, Gene Transfer by Electroporation, Molecular Biotechnology, vol. 7, 1997.
Lynn, et al., A New Method for the Generation and Use of Focused Ultrasound in Experimental Biology, The Journal of General Physiology, vol. 26, 179-193, 1942.
Miklav{hacek over (c)}i{hacek over (c)}, et al., A Validated Model of an in Vivo Electric Field Distribution in Tissues for Electrochemotherapy and for DNA Electrotransfer for Gene Therapy, Biochimica et Biophysica Acta 1523 (2000), pp. 73-83.
Miklav{hacek over (c)}i{hacek over (c)}, et al., The Importance of Electric Field Distribution for Effective in Vivo Electroporation of Tissues, Biophysical Journal, vol. 74, May 1998, pp. 2152-2158.
Miller, L., et al., Cancer cells ablation with irreversible electroporation, Technology in Cancer Research and Treatment 4 (2005) 699-706.
Mir, et al., Effective Treatment of Cutaneous and Subcutaneous Malignant Tumours by Electrochemotherapy, British Journal of Cancer, vol. 77, No. 12, pp. 2336-2342, 1998.
Mir, et al., Electrochemotherapy Potentiation of Antitumour Effect of Bleomycin by Local Electric Pulses, European Journal of Cancer, vol. 27, No. 1, pp. 68-72, 1991.
Mir, et al., Electrochemotherapy, a Novel Antitumor Treatment: First Clinical Trial, C.R. Acad. Sci. Paris, Ser. III, vol. 313, pp. 613-618, 1991.
Mir, L.M. And Orlowski, S., The basis of electrochemotherapy, in Electrochemotherapy, electrogenetherapy, and transdermal drug delivery: electrically mediated delivery of molecules to cells, M.J. Jaroszeski, R. Heller, R. Gilbert, Editors, 2000, Humana Press, p. 99-118.
Mir, L.M., et al., Electric Pulse-Mediated Gene Delivery to Various Animal Tissues, in Advances in Genetics, Academic Press, 2005, p. 83-114.
Mir, Therapeutic Perspectives of In Vivo Cell Electropermeabilization, Bioelectrochemistry, vol. 53, pp. 1-10, 2000.
Narayan, et al., Establishment and Characterization of a Human Primary Prostatic Adenocarcinoma Cell Line (ND-1), The Journal of Urology, vol. 148, 1600-1604, Nov. 1992.
Naslund, Cost-Effectiveness of Minimally Invasive Treatments and Transurethral Resection (TURP) in Benign Prostatic Hyperplasia (BPH), (Abstract), Presented at 2001 AUA National Meeting,, Anaheim, CA, Jun. 5, 2001.
Naslund, Michael J., Transurethral Needle Ablation of the Prostate, Urology, vol. 50, No. 2, Aug. 1997.
Neumann, et al., Gene Transfer into Mouse Lyoma Cells by Electroporation in High Electric Fields, J. Embo., vol. 1, No. 7, pp. 841-845, 1982.
Neumann, et al., Permeability Changes Induced by Electric Impulses in Vesicular Membranes, J. Membrane Biol., vol. 10, pp. 279-290, 1972.
Okino, et al., Effects of High-Voltage Electrical Impulse and an Anticancer Drug on In Vivo Growing Tumors, Japanese Journal of Cancer Research, vol. 78, pp. 1319-1321, 1987.
Onik, et al., Sonographic Monitoring of Hepatic Cryosurgery in an Experimental Animal Model, AJR American J. of Roentgenology, vol. 144, pp. 1043-1047, May 1985.
Onik, et al., Ultrasonic Characteristics of Frozen Liver, Cryobiology, vol. 21, pp. 321-328, 1984.
Organ, L.W., Electrophysiological principles of radiofrequency lesion making, Apply. Neurophysiol., 1976. 39: p. 69-76.
Piñero, et al., Apoptotic and Necrotic Cell Death Are Both Induced by Electroporation in HL60 Human Promyeloid Leukaemia Cells, Apoptosis, vol, 2, No. 3, 330-336, Aug. 1997.
Precision Office TUNA System, When Patient Satisfaction is Your Goal.
Rols, M.P., et al., Highly Efficient Transfection of Mammalian Cells by Electric Field Pulses: Application to Large Volumes of Cell Culture by Using a Flow System, Eur. J. Biochem. 1992, 206, pp. 115-121.
Rubinsky, B., ed, Cryosurgery. Annu Rev. Biomed. Eng. vol. 2 2000. 157-187.
Schmukler, Impedance Spectroscopy of Biological Cells, downloaded from IEEE Xplore website.
Sersa, et al., Reduced Blood Flow and Oxygenation in SA-1 Tumours after Electrochemotherapy with Cisplatin, British Journal of Cancer, 87, 1047-1054, 2002.
Sersa, et al., Tumour Blood Flow Modifying Effects of Electrochemotherapy: a Potential Vascular Targeted Mechanism, Radiol. Oncol., 37(1): 43-8, 2003.
Sharma, et al., Poloxamer 188 Decreases Susceptibility of Artificial Lipid Membranes to Electroporation, Biophysical Journal, vol. 71, No. 6, pp. 3229-3241, Dec. 1996.
Shiina, S., et al, Percutaneous ethanol injection therapy for hepatocellular carcinoma: results in 146 patients. AJR, 1993, 160: p. 1023-8.
Thompson, et al., To determine whether the temperature of 2% lignocaine gel affects the initial discomfort which may be associated with its instillation into the male urethra, BJU International (1999), 84, 1035-1037.
TUNA-Suggested Local Anesthesia Guidelines.
Vidamed, Inc., Transurethral Needle Ablation (TUNA): Highlights from Worldwide Clinical Studies, Vidamed's Office TUNA System.
Weaver, Electroporation: A General Phenomenon for Manipulating Cells and Tissues, Journal of Cellular Biochemistry, 51: 426-435, 1993.
Weaver, et al., Theory of Electroporation: A Review, Bioelectrochemistry and Bioenergetics, vol. 41, pp. 136-160, 1996.
Zimmermann, et al., Dielectric Breakdown of Cell Membranes, Biophysical Journal, vol. 14, No. 11, pp. 881-899, 1974.
Zlotta, et al., Long-Term Evaluation of Transurethral Needle Ablation of the Prostate (TUNA) for Treatment of Benign Prostatic Hyperplasia (BPH): Clinical Outcome After 5 Years. (Abstract) Presented at 2001 AUA National Meeting, Anaheim, CA-Jun. 5, 2001.
Zlotta, et al., Possible Mechanisms of Action of Transurethral Needle Ablation of the Prostate on Benign Prostatic Hyperplasia Symptoms: a Neurohistochemical Study, Reprinted from Journal of Urology, vol. 157, No. 3, Mar. 1997, pp. 894-899.

Cited By (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12070411B2 (en) 2006-04-28 2024-08-27 Zeltiq Aesthetics, Inc. Cryoprotectant for use with a treatment device for improved cooling of subcutaneous lipid-rich cells
US11395760B2 (en) 2006-09-26 2022-07-26 Zeltiq Aesthetics, Inc. Tissue treatment methods
US11986421B2 (en) 2006-09-26 2024-05-21 Zeltiq Aesthetics, Inc. Cooling devices with flexible sensors
US9375345B2 (en) 2006-09-26 2016-06-28 Zeltiq Aesthetics, Inc. Cooling device having a plurality of controllable cooling elements to provide a predetermined cooling profile
US10292859B2 (en) 2006-09-26 2019-05-21 Zeltiq Aesthetics, Inc. Cooling device having a plurality of controllable cooling elements to provide a predetermined cooling profile
US11219549B2 (en) 2006-09-26 2022-01-11 Zeltiq Aesthetics, Inc. Cooling device having a plurality of controllable cooling elements to provide a predetermined cooling profile
US11179269B2 (en) 2006-09-26 2021-11-23 Zeltiq Aesthetics, Inc. Cooling device having a plurality of controllable cooling elements to provide a predetermined cooling profile
US11291606B2 (en) 2007-05-18 2022-04-05 Zeltiq Aesthetics, Inc. Treatment apparatus for removing heat from subcutaneous lipid-rich cells and massaging tissue
US10383787B2 (en) 2007-05-18 2019-08-20 Zeltiq Aesthetics, Inc. Treatment apparatus for removing heat from subcutaneous lipid-rich cells and massaging tissue
US9655770B2 (en) 2007-07-13 2017-05-23 Zeltiq Aesthetics, Inc. System for treating lipid-rich regions
US9408745B2 (en) 2007-08-21 2016-08-09 Zeltiq Aesthetics, Inc. Monitoring the cooling of subcutaneous lipid-rich cells, such as the cooling of adipose tissue
US11583438B1 (en) 2007-08-21 2023-02-21 Zeltiq Aesthetics, Inc. Monitoring the cooling of subcutaneous lipid-rich cells, such as the cooling of adipose tissue
US10675178B2 (en) 2007-08-21 2020-06-09 Zeltiq Aesthetics, Inc. Monitoring the cooling of subcutaneous lipid-rich cells, such as the cooling of adipose tissue
US10828085B2 (en) 2008-04-29 2020-11-10 Virginia Tech Intellectual Properties, Inc. Immunotherapeutic methods using irreversible electroporation
US10286108B2 (en) 2008-04-29 2019-05-14 Virginia Tech Intellectual Properties, Inc. Irreversible electroporation to create tissue scaffolds
US9867652B2 (en) 2008-04-29 2018-01-16 Virginia Tech Intellectual Properties, Inc. Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds
US11655466B2 (en) 2008-04-29 2023-05-23 Virginia Tech Intellectual Properties, Inc. Methods of reducing adverse effects of non-thermal ablation
US11607271B2 (en) 2008-04-29 2023-03-21 Virginia Tech Intellectual Properties, Inc. System and method for estimating a treatment volume for administering electrical-energy based therapies
US11453873B2 (en) 2008-04-29 2022-09-27 Virginia Tech Intellectual Properties, Inc. Methods for delivery of biphasic electrical pulses for non-thermal ablation
US10117707B2 (en) 2008-04-29 2018-11-06 Virginia Tech Intellectual Properties, Inc. System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies
US10154874B2 (en) 2008-04-29 2018-12-18 Virginia Tech Intellectual Properties, Inc. Immunotherapeutic methods using irreversible electroporation
US11890046B2 (en) 2008-04-29 2024-02-06 Virginia Tech Intellectual Properties, Inc. System and method for ablating a tissue site by electroporation with real-time monitoring of treatment progress
US10238447B2 (en) 2008-04-29 2019-03-26 Virginia Tech Intellectual Properties, Inc. System and method for ablating a tissue site by electroporation with real-time monitoring of treatment progress
US10245098B2 (en) 2008-04-29 2019-04-02 Virginia Tech Intellectual Properties, Inc. Acute blood-brain barrier disruption using electrical energy based therapy
US10245105B2 (en) 2008-04-29 2019-04-02 Virginia Tech Intellectual Properties, Inc. Electroporation with cooling to treat tissue
US10272178B2 (en) 2008-04-29 2019-04-30 Virginia Tech Intellectual Properties Inc. Methods for blood-brain barrier disruption using electrical energy
US12059197B2 (en) 2008-04-29 2024-08-13 Virginia Tech Intellectual Properties, Inc. Blood-brain barrier disruption using reversible or irreversible electroporation
US11952568B2 (en) 2008-04-29 2024-04-09 Virginia Tech Intellectual Properties, Inc. Device and methods for delivery of biphasic electrical pulses for non-thermal ablation
US9598691B2 (en) 2008-04-29 2017-03-21 Virginia Tech Intellectual Properties, Inc. Irreversible electroporation to create tissue scaffolds
US11272979B2 (en) 2008-04-29 2022-03-15 Virginia Tech Intellectual Properties, Inc. System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies
US11737810B2 (en) 2008-04-29 2023-08-29 Virginia Tech Intellectual Properties, Inc. Immunotherapeutic methods using electroporation
US10470822B2 (en) 2008-04-29 2019-11-12 Virginia Tech Intellectual Properties, Inc. System and method for estimating a treatment volume for administering electrical-energy based therapies
US11254926B2 (en) 2008-04-29 2022-02-22 Virginia Tech Intellectual Properties, Inc. Devices and methods for high frequency electroporation
US10828086B2 (en) 2008-04-29 2020-11-10 Virginia Tech Intellectual Properties, Inc. Immunotherapeutic methods using irreversible electroporation
US10537379B2 (en) 2008-04-29 2020-01-21 Virginia Tech Intellectual Properties, Inc. Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds
US10959772B2 (en) 2008-04-29 2021-03-30 Virginia Tech Intellectual Properties, Inc. Blood-brain barrier disruption using electrical energy
US11974800B2 (en) 2008-04-29 2024-05-07 Virginia Tech Intellectual Properties, Inc. Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds
US9737434B2 (en) 2008-12-17 2017-08-22 Zeltiq Aestehtics, Inc. Systems and methods with interrupt/resume capabilities for treating subcutaneous lipid-rich cells
US10448989B2 (en) 2009-04-09 2019-10-22 Virginia Tech Intellectual Properties, Inc. High-frequency electroporation for cancer therapy
US10292755B2 (en) 2009-04-09 2019-05-21 Virginia Tech Intellectual Properties, Inc. High frequency electroporation for cancer therapy
US11382681B2 (en) 2009-04-09 2022-07-12 Virginia Tech Intellectual Properties, Inc. Device and methods for delivery of high frequency electrical pulses for non-thermal ablation
US11638603B2 (en) 2009-04-09 2023-05-02 Virginia Tech Intellectual Properties, Inc. Selective modulation of intracellular effects of cells using pulsed electric fields
US11452634B2 (en) 2009-04-30 2022-09-27 Zeltiq Aesthetics, Inc. Device, system and method of removing heat from subcutaneous lipid-rich cells
US8702774B2 (en) 2009-04-30 2014-04-22 Zeltiq Aesthetics, Inc. Device, system and method of removing heat from subcutaneous lipid-rich cells
US11224536B2 (en) 2009-04-30 2022-01-18 Zeltiq Aesthetics, Inc. Device, system and method of removing heat from subcutaneous lipid-rich cells
US9861520B2 (en) 2009-04-30 2018-01-09 Zeltiq Aesthetics, Inc. Device, system and method of removing heat from subcutaneous lipid-rich cells
US11707629B2 (en) 2009-05-28 2023-07-25 Angiodynamics, Inc. System and method for synchronizing energy delivery to the cardiac rhythm
US9895189B2 (en) 2009-06-19 2018-02-20 Angiodynamics, Inc. Methods of sterilization and treating infection using irreversible electroporation
US9844461B2 (en) 2010-01-25 2017-12-19 Zeltiq Aesthetics, Inc. Home-use applicators for non-invasively removing heat from subcutaneous lipid-rich cells via phase change coolants
US9314368B2 (en) 2010-01-25 2016-04-19 Zeltiq Aesthetics, Inc. Home-use applicators for non-invasively removing heat from subcutaneous lipid-rich cells via phase change coolants, and associates devices, systems and methods
US8676338B2 (en) 2010-07-20 2014-03-18 Zeltiq Aesthetics, Inc. Combined modality treatment systems, methods and apparatus for body contouring applications
US10092346B2 (en) 2010-07-20 2018-10-09 Zeltiq Aesthetics, Inc. Combined modality treatment systems, methods and apparatus for body contouring applications
US11931096B2 (en) 2010-10-13 2024-03-19 Angiodynamics, Inc. System and method for electrically ablating tissue of a patient
US10702326B2 (en) 2011-07-15 2020-07-07 Virginia Tech Intellectual Properties, Inc. Device and method for electroporation based treatment of stenosis of a tubular body part
US9757196B2 (en) 2011-09-28 2017-09-12 Angiodynamics, Inc. Multiple treatment zone ablation probe
US11779395B2 (en) 2011-09-28 2023-10-10 Angiodynamics, Inc. Multiple treatment zone ablation probe
US12102376B2 (en) 2012-02-08 2024-10-01 Angiodynamics, Inc. System and method for increasing a target zone for electrical ablation
US9888956B2 (en) 2013-01-22 2018-02-13 Angiodynamics, Inc. Integrated pump and generator device and method of use
US9545523B2 (en) 2013-03-14 2017-01-17 Zeltiq Aesthetics, Inc. Multi-modality treatment systems, methods and apparatus for altering subcutaneous lipid-rich tissue
US9844460B2 (en) 2013-03-14 2017-12-19 Zeltiq Aesthetics, Inc. Treatment systems with fluid mixing systems and fluid-cooled applicators and methods of using the same
US11957405B2 (en) 2013-06-13 2024-04-16 Angiodynamics, Inc. Methods of sterilization and treating infection using irreversible electroporation
US10912599B2 (en) 2014-01-31 2021-02-09 Zeltiq Aesthetics, Inc. Compositions, treatment systems and methods for improved cooling of lipid-rich tissue
US11819257B2 (en) 2014-01-31 2023-11-21 Zeltiq Aesthetics, Inc. Compositions, treatment systems and methods for improved cooling of lipid-rich tissue
US10201380B2 (en) 2014-01-31 2019-02-12 Zeltiq Aesthetics, Inc. Treatment systems, methods, and apparatuses for improving the appearance of skin and providing other treatments
US10806500B2 (en) 2014-01-31 2020-10-20 Zeltiq Aesthetics, Inc. Treatment systems, methods, and apparatuses for improving the appearance of skin and providing other treatments
US10575890B2 (en) 2014-01-31 2020-03-03 Zeltiq Aesthetics, Inc. Treatment systems and methods for affecting glands and other targeted structures
US9861421B2 (en) 2014-01-31 2018-01-09 Zeltiq Aesthetics, Inc. Compositions, treatment systems and methods for improved cooling of lipid-rich tissue
US10675176B1 (en) 2014-03-19 2020-06-09 Zeltiq Aesthetics, Inc. Treatment systems, devices, and methods for cooling targeted tissue
USD777338S1 (en) 2014-03-20 2017-01-24 Zeltiq Aesthetics, Inc. Cryotherapy applicator for cooling tissue
US10471254B2 (en) 2014-05-12 2019-11-12 Virginia Tech Intellectual Properties, Inc. Selective modulation of intracellular effects of cells using pulsed electric fields
US11406820B2 (en) 2014-05-12 2022-08-09 Virginia Tech Intellectual Properties, Inc. Selective modulation of intracellular effects of cells using pulsed electric fields
US10952891B1 (en) 2014-05-13 2021-03-23 Zeltiq Aesthetics, Inc. Treatment systems with adjustable gap applicators and methods for cooling tissue
US10935174B2 (en) 2014-08-19 2021-03-02 Zeltiq Aesthetics, Inc. Stress relief couplings for cryotherapy apparatuses
US10568759B2 (en) 2014-08-19 2020-02-25 Zeltiq Aesthetics, Inc. Treatment systems, small volume applicators, and methods for treating submental tissue
US12114911B2 (en) 2014-08-28 2024-10-15 Angiodynamics, Inc. System and method for ablating a tissue site by electroporation with real-time pulse monitoring
US11903690B2 (en) 2014-12-15 2024-02-20 Virginia Tech Intellectual Properties, Inc. Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment
US10694972B2 (en) 2014-12-15 2020-06-30 Virginia Tech Intellectual Properties, Inc. Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment
US11154418B2 (en) 2015-10-19 2021-10-26 Zeltiq Aesthetics, Inc. Vascular treatment systems, cooling devices, and methods for cooling vascular structures
US10524956B2 (en) 2016-01-07 2020-01-07 Zeltiq Aesthetics, Inc. Temperature-dependent adhesion between applicator and skin during cooling of tissue
US10765552B2 (en) 2016-02-18 2020-09-08 Zeltiq Aesthetics, Inc. Cooling cup applicators with contoured heads and liner assemblies
US10555831B2 (en) 2016-05-10 2020-02-11 Zeltiq Aesthetics, Inc. Hydrogel substances and methods of cryotherapy
US11382790B2 (en) 2016-05-10 2022-07-12 Zeltiq Aesthetics, Inc. Skin freezing systems for treating acne and skin conditions
US10682297B2 (en) 2016-05-10 2020-06-16 Zeltiq Aesthetics, Inc. Liposomes, emulsions, and methods for cryotherapy
US10939958B2 (en) 2016-06-27 2021-03-09 Galary, Inc. Methods, apparatuses, and systems for the treatment of pulmonary disorders
US11369433B2 (en) 2016-06-27 2022-06-28 Galvanize Therapeutics, Inc. Methods, apparatuses, and systems for the treatment of pulmonary disorders
US10702337B2 (en) 2016-06-27 2020-07-07 Galary, Inc. Methods, apparatuses, and systems for the treatment of pulmonary disorders
US11723710B2 (en) 2016-11-17 2023-08-15 Angiodynamics, Inc. Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode
US11076879B2 (en) 2017-04-26 2021-08-03 Zeltiq Aesthetics, Inc. Shallow surface cryotherapy applicators and related technology
US11607537B2 (en) 2017-12-05 2023-03-21 Virginia Tech Intellectual Properties, Inc. Method for treating neurological disorders, including tumors, with electroporation
US11311329B2 (en) 2018-03-13 2022-04-26 Virginia Tech Intellectual Properties, Inc. Treatment planning for immunotherapy based treatments using non-thermal ablation techniques
US11925405B2 (en) 2018-03-13 2024-03-12 Virginia Tech Intellectual Properties, Inc. Treatment planning system for immunotherapy enhancement via non-thermal ablation
US12102557B2 (en) 2018-07-31 2024-10-01 Zeltiq Aesthetics, Inc. Methods, devices, and systems for improving skin characteristics
US11446175B2 (en) 2018-07-31 2022-09-20 Zeltiq Aesthetics, Inc. Methods, devices, and systems for improving skin characteristics
US11950835B2 (en) 2019-06-28 2024-04-09 Virginia Tech Intellectual Properties, Inc. Cycled pulsing to mitigate thermal damage for multi-electrode irreversible electroporation therapy

Also Published As

Publication number Publication date
US20030153960A1 (en) 2003-08-14
US6795728B2 (en) 2004-09-21

Similar Documents

Publication Publication Date Title
USRE43009E1 (en) Apparatus and method for reducing subcutaneous fat deposits by electroporation
US10335224B2 (en) Method of destroying tissue cells by electroporation
USRE42835E1 (en) Apparatus and method for reducing subcutaneous fat deposits by electroporation with improved comfort of patients
US6892099B2 (en) Apparatus and method for reducing subcutaneous fat deposits, virtual face lift and body sculpturing by electroporation
US7267676B2 (en) Method for hair removal by electroporation
US6463323B1 (en) Electrically mediated angiogenesis
US6068650A (en) Method of Selectively applying needle array configurations
WO2000023143A1 (en) Apparatus for electroporation mediated delivery of drugs and genes
BR112015021939A2 (en) ELECTRICAL AND HYDRAULIC GENERATOR (EH) OF FAST PULSE SHOCK WAVES AND METHOD
ATE292492T1 (en) METHOD AND DEVICE FOR ELECTRICALLY STIMULATING TISSUE
JP2009506873A (en) Apparatus and method for disrupting subcutaneous structures
WO2020077019A1 (en) Treatment of dermal glands by the application of non-thermal energy
KR20080005968A (en) Dc tissue treatment
CA2339371C (en) Electrically mediated angiogenesis
WO2009073017A1 (en) Use of iontophoresis and ultrasound to deliver melanin or other chromophores for laser hair revoval
US6039746A (en) Patch electrolysis system and method for removing hair from skin
US20210401489A1 (en) Tattoo removal
RU2055554C1 (en) Method of curing partially atrophied optic nerve

Legal Events

Date Code Title Description
REMI Maintenance fee reminder mailed
AS Assignment

Owner name: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT

Free format text: SECURITY AGREEMENT;ASSIGNOR:ANGIODYNAMICS, INC.;REEL/FRAME:028260/0329

Effective date: 20120522

FPAY Fee payment

Year of fee payment: 8

SULP Surcharge for late payment

Year of fee payment: 7

AS Assignment

Owner name: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT, ILLINOIS

Free format text: SECURITY AGREEMENT;ASSIGNOR:ANGIODYNAMICS, INC.;REEL/FRAME:031315/0720

Effective date: 20130919

Owner name: ANGIODYNAMICS, INC., NEW YORK

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:JPMORGAN CHASE BANK N.A., AS ADMINISTRATIVE AGENT;REEL/FRAME:031315/0361

Effective date: 20130919

Owner name: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT

Free format text: SECURITY AGREEMENT;ASSIGNOR:ANGIODYNAMICS, INC.;REEL/FRAME:031315/0720

Effective date: 20130919

FPAY Fee payment

Year of fee payment: 12

AS Assignment

Owner name: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT, ILLINOIS

Free format text: SECURITY INTEREST;ASSIGNOR:ANGIODYNAMICS, INC.;REEL/FRAME:040613/0049

Effective date: 20161107

Owner name: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT

Free format text: SECURITY INTEREST;ASSIGNOR:ANGIODYNAMICS, INC.;REEL/FRAME:040613/0049

Effective date: 20161107

AS Assignment

Owner name: ANGIODYNAMICS, INC., NEW YORK

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT;REEL/FRAME:040688/0540

Effective date: 20161107

AS Assignment

Owner name: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT

Free format text: CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS;ASSIGNOR:ANGIODYNAMICS, INC.;REEL/FRAME:049371/0657

Effective date: 20190603

Owner name: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT, ILLINOIS

Free format text: CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS;ASSIGNOR:ANGIODYNAMICS, INC.;REEL/FRAME:049371/0657

Effective date: 20190603

AS Assignment

Owner name: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT, ILLINOIS

Free format text: SECURITY INTEREST;ASSIGNOR:ANGIODYNAMICS, INC.;REEL/FRAME:061360/0668

Effective date: 20220830

Owner name: ANGIODYNAMICS, INC., NEW YORK

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT;REEL/FRAME:061363/0446

Effective date: 20220830

AS Assignment

Owner name: ANGIODYNAMICS, INC., NEW YORK

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT;REEL/FRAME:063940/0362

Effective date: 20230608